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Introduction: Multiple myeloma (MM) is a relatively common and incurable hematological 
malignancy. Currently, there is no single standard therapy, with choice of treatment dependent on 
individual patient factors. Lenalidomide is an immunomodulatory drug with potent antitumor, 
antiangiogenic, immunomodulatory, and proapoptotic activity in MM.
Aims: To evaluate the evidence for the use of lenalidomide in its current indication in 
relapsed or refractory MM, and additionally its investigational use for the treatment of newly 
diagnosed MM.
Evidence review: In patients with relapsed and refractory MM, adding lenalidomide to 
high-dose dexamethasone significantly improves response rates and time-to-progression, relative 
to high-dose dexamethasone alone. This translates into a significant extension of overall survival 
(with a median extension of 9.1 months in a pivotal phase III study). Outcome is independent 
of patient age, number of previous therapies, type of previous therapy (including thalidomide or 
autologous stem cell transplantation), renal impairment, and β2-microglobulin level. Evidence 
suggests that combining lenalidomide with low-dose dexamethasone improves outcomes in 
patients with newly diagnosed disease and is superior to lenalidomide combined with high-
dose dexamethasone. Myelosuppression is the predominant toxicity observed, although some 
studies have shown high incidences of venous thromboembolism in the absence of prophylactic 
antithrombotic anticoagulation therapy. There is currently only limited evidence regarding the 
health economics of lenalidomide.
Role in therapy: The encouraging results obtained with lenalidomide alone and in combination with 
dexamethasone in patients with relapsed or refractory MM have led to its adoption as a recommended 
therapy in patients who have received at least one prior treatment. Emerging evidence supports the 
ongoing investigation of lenalidomide in combination with low-dose dexamethasone, and in other com-
binations including bortezomib, for use both in relapsed, refractory, and newly diagnosed MM.
Keywords: lenalidomide, evidence, multiple myeloma, outcomes, treatment
Core evidence clinical impact summary for lenalidomide in relapsed, refractory 
multiple myeloma
Outcome measure Evidence Implications
Patient-oriented evidence
Prolongation of OS Substantial Median OS is significantly longer with 
lenalidomide plus dexamethasone than with 
dexamethasone alone
Prolongation of TTP Substantial Median TTP is significantly longer with 
lenalidomide plus dexamethasone than with 
dexamethasone alone
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Scope, aims, and objectives
Lenalidomide1 in combination with dexamethasone is 
indicated for the treatment of multiple myeloma (MM) in 
patients who have received at least one prior therapy.2,3 This 
review provides a background to MM, summarizes current 
therapies and unmet needs, and evaluates the current evidence 
for the use of lenalidomide. Disease-oriented outcomes 
are evaluated, including response rates, response duration, 
time-to-progression (TTP), overall survival (OS), and 
one-year survival, as well as safety and tolerability. A search 
of the literature to-date did not identify any studies with 
patient-reported outcomes, such as quality of life, functional 
status, treatment satisfaction, adherence, or symptom relief. 
These parameters of clinical benefit are therefore not included 
in this review.
Methods
The English language medical literature was reviewed to 
identify abstracts and articles relating to lenalidomide in MM. 
Relevant databases were searched on  April 11th, 2008 using 
the search terms “lenalidomide OR Revlimid OR CC-5013 
AND ‘multiple myeloma’”. Each database was searched from 
the beginning of the database to the date of the search, unless 
otherwise specified. The following databases, including 
proceedings of oncology-based meetings, were searched for 
relevant abstracts and full text articles:
•  PubMed, http://www.ncbi.nlm.nih.gov/entrez
•  Cochrane Database of Systematic Reviews (CDSR), 
http://www.cochrane.org
•  ClinicalTrials.gov clinical trial register, http://www.
clinicaltrials.gov
•  ClinicalStudyResults.org clinical trial register, http://
www.clinicalstudyresults.org
•  American Society of Hematology (ASH), 2005–2007, 
http://bloodjournal.hematologylibrary.org/search.dtl
•  International Myeloma Working Group (IMWG), 2007
•  European Hematology Association (EHA), 2008, http://
www.ehaweb.org/
•  American Society of Clinical Oncology (ASCO), 
2005–2007, http://www.asco.org/portal/site/ASCO
An additional search of the English language literature 
on PubMed conducted on April 11, 2008 was further refined 
to provide specificity for the search using the limits “clinical 
trial”, “meta analysis”, “randomized controlled trial”, and 
“humans”. The original PubMed search yielded 228 records 
including abstracts, and was subsequently narrowed 
to 18 records with these limits imposed. Six records were 
excluded from these 18 records for reasons of relevance 
(n = 2), incorrect indication (n = 3), and nonsystematic review 
(n = 1). A further search of PubMed conducted on September 1, 
2008 and time-limited from the previous search but otherwise 
using the same limits yielded one additional record, which 
was included. A similar search of the ASCO website on 
the same day yielded 13 additional abstracts, while hand-
searching of the European Hematology Association (EHA; 
http://www.ehaweb.org/) 2008 meeting abstracts produced 
10 new abstracts. Eighteen of these records were included in 
the clinical evidence. No systematic reviews were identified 
(Continued )
Outcome measure Evidence Implications
Adverse events Substantial A significantly higher proportion of patients 
treated with lenalidomide plus dexametha-
sone report grade 3 or 4 adverse events, 
with neutropenia, thrombocytopenia, anemia, 
and venous thromboembolic events being the 
most important




improvement in response  





A significantly higher proportion of patients 
treated with lenalidomide plus dexametha-
sone compared with dexamethasone alone 
respond to treatment
Economic evidence 





Direct drug costs of the approved lenalido-
mide regimen appear to be similar to or 
higher than related novel agent regimens
Cost effectiveness No evidence
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for the use of lenalidomide in MM. Two papers and 18 
abstracts were of level 2 evidence, and another 11 papers 
and 25 abstracts were of level 3 evidence. The levels of 
evidence identified from the literature searches are summa-
rized in Table 1. Criteria for exclusion were nonsystematic 
reviews, case studies, case series, phase I clinical trials or 
interim analyses of phase I/II clinical trials, and duplicate 
abstracts defined as presentation of similar data in the same 
calendar year. Substudy analyses were included at the same 
level of evidence as for the original study. Descriptive and 
observational studies, including retrospective studies, were 
included only for evaluation of safety.
Disease overview
MM is a hematological malignancy of plasma cells 
characterized by clonal expansion, bone marrow infiltration, 
lytic bone disease, hypercalcemia, renal insufficiency, and the 
presence, in the vast majority of patients, of immunoglobulin 
paraproteins (M-protein) in the serum and/or urine.4 The 
disease arises from a B-cell of the normal germinal center as a 
result of a chromosomal translocation that places an oncogene 
under the control of immunoglobulin enhancers.5 Despite 
recent therapeutic advances, including high-dose chemotherapy 
and autologous stem cell transplantation (SCT), MM is an 
incurable disease with a median overall survival (OS) of three 
to four years and a five-year relative survival of approximately 
33% in 2007.6,7 During the past 10 years, survival rates for 
MM have increased; however, relapse remains inevitable and, 
until recently, there were few effective salvage therapies.8 
Novel treatment options, such as thalidomide, bortezomib, 
and lenalidomide, are increasingly recognized as important 
and potent new therapies in overcoming resistant disease and 
contributing to improved outcome.8,9
Epidemiology
In the US, MM is the second most common hematologic 
malignancy after non-Hodgkin’s lymphoma, with an esti-
mated 19,920 new cases in 2008.10 This figure represents 
about 1.4% of all new cancer cases, including 14% of new 
hematologic malignancies.10 However, with a median sur-
vival in the order of three to four years,6 the disease claims 
a higher proportion of cancer-related deaths, estimated at 
10,690 or 2% of all cancer deaths, including 20% of deaths 
due to hematologic malignancies.10
MM is predominantly a disease of older patients, with 
a mean age at diagnosis of 70 years.11 During 2000–2005, 
approximately 64% of diagnoses of MM were in people 
aged 65 years and older, and around 96% were in people 
aged 45 years and older. Although age is the most significant 
risk factor for MM, disease incidence is also higher among 
men than women (7.0 vs 4.6 per 100,000, respectively) 
and among African-Americans than Caucasian Americans 
(men: 14.4 vs 6.6 per 100,000, respectively; females: 9.8 vs 
4.1 per 100,000, respectively).11 The economic burden of 
MM has yet to be well described, but its high mortality and 
considerable antecedent morbidity is likely to make this 
substantial.
Clinical features
MM can be classified on the basis of symptoms, with 
symptomatic disease requiring evidence of related organ- 
or tissue-impairment, which is typically manifested by 
increased calcium, renal insufficiency, anemia, and/or bone 
lesions secondary to the plasma cell proliferative process.12 
Other symptoms include bone pain, fatigue, fractures, 
recurrent infections, and weakness. Although the detection 
of immunoglobulin M-protein is characteristic, this is 
patient-specific and is absent in the 1%–2% of patients with 
nonsecretory MM.4 In asymptomatic or smoldering MM, 
M-protein and/or bone marrow clonal cells are present, 
but there is no related organ- or tissue-impairment. Up to 
25% of patients may have a smoldering pattern of disease 
at presentation.13
Diagnosis
A diagnosis of MM is often made incidentally during 
investigations of other conditions or as part of routine 
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 228 216
  Records excluded 216 191
  Records included 12 25
Search update, new records 1 23
  Records excluded 0 5
  Records included 1 18
Level 1 clinical evidence 0 0
Level 2 clinical evidence 2 18
Level  3 clinical evidence 11 25
  Trials other than RCT 11 25
  Case reports 0 0
Economic evidence 0 3
Notes: For definition of levels of evidence, see Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbreviation: RCT, randomized clinical controlled trial.Core Evidence 2009:4 218
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screening, as overt features of the disease may be absent. 
Assessment of serum and urine samples for M-proteins helps 
to establish a diagnosis, with immunofixation considered 
the gold standard when looking to confirm the presence 
of M-proteins and to distinguish heavy versus light chain 
types.12 Monoclonal gammopathies need to be excluded 
from polyclonal gammopathies because only the former 
are associated with neoplasia or potential neoplastic events. 
Serum protein electrophoresis is a suitable screening assay for 
M-protein whenever MM or related disorders are suspected, 
or in the presence of unexplained weakness, fatigue, anemia, 
infection, back pain, osteopenia, osteolytic lesions, or spon-
taneous fractures.12 Elevation of erythrocyte sedimentation 
rate, increased serum viscosity, hypergammaglobulinemia, 
hypercalcemia, Bence Jones proteinuria, renal insufficiency, 
and immunoglobulin deficiency (especially in the context 
of recurrent infection) may also be indicative and warrant 
screening for M-protein. Studies should include complete 
blood count, serum chemistry, bone marrow aspirate, and 
trephine biopsy for cytogenetic analysis of immunoglobulin 
translocations, as well as fluorescence in situ hybridization 
(FISH) and assessment of β2-microglobulin, C-reactive 
protein, and lactate dehydrogenase.12
A diagnosis of MM requires M-protein levels of 30 g/L 
and/or 10% or more plasma cells in the bone marrow.12 
When these features are present together with related 
organ- or tissue-impairment, a diagnosis of symptomatic 
(versus asymptomatic) MM may be applied. Any patient with a 
serum M-protein level of 30 g/L and/or 10% clonal plasma 
cells in the bone marrow in the absence of myeloma-related 
organ- or tissue-impairment is considered to have monoclonal 
gammopathy of undetermined significance (MGUS).
Disease staging
Two main staging systems are currently in use in MM, the 
International Staging System (ISS) and the Durie–Salmon 
system.6,14 The staging system most widely used since 1975 
is the Durie–Salmon system, which is based on four clinical 
parameters that predict tumor burden: hemoglobin level; 
serum calcium level; number of bone lesions; and M-protein 
levels14 (Table 2). Serum creatinine level is additionally used 
to sub-categorize patients in each of the three stages accord-
ing to renal function.
Although the Durie–Salmon system remains in widespread 
use, it is limited by observer dependence on assessments of the 
number of lytic lesions, by the characterization of new prog-
nostic factors, and some redundancy. With respect to the latter, 
patients with stage I disease are not separated from those with 
smoldering myeloma in that neither group requires immediate 
treatment.15 Similarly, patients with either stage II or III disease 
Table 2 The Durie–Salmon and international Staging System multiple myeloma staging systems6,14
Stage Durie–Salmon criteria ISS criteria
i All of the following: Serum β2-M  3.5 mg/L and serum albumin 3.5 g/dL
  •  Hemoglobin 10 g/dL
  •    Serum calcium normal or 12 mg/dL
  •    Bone x-ray: normal bone structure (scale 0) or  
solitary bone plasmacytoma only
  •    Low M-component production rate: igG  5 g/dL;  
igA  3 g/dL; and Bence Jones protein 4 g/24 hours
ii Neither stage i nor stage iii Neither stage i nor stage iii according to the following 
subcategories:
  •    Serum β2-M  3.5 mg/L and serum albumin 3.5 g/dL;
or
  •    Serum β2-M 3.5–5.5 mg/L irrespective of serum  
albumin level
iii One or more of the following: Serum β2-M  5.5 mg/L
  •  Hemoglobin 8.5 g/dL
  •    Serum calcium 12 mg/dL
  •   Advanced lytic bone lesions (scale 3)
  •    High M-component production rate: igG  7 g/dL;  
igA  5 g/dL; Bence Jones protein 12 g/24 hours
Notes: *Durie-Salmon sub-classifications (either A or B): A: serum creatinine 2.0 mg/dL; and B: serum creatinine 2.0 mg/dL.
Abbreviations: β2-M, β2-microglobulin; ig, immunoglobulin; iSS, international Staging System.Core Evidence 2009:4 219
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typically have active, symptomatic myeloma. Moreover, with the 
recognition of the prognostic value of serum β2-microglobulin 
and serum albumin, clinicians are increasingly complementing 
the Durie–Salmon system with the ISS.6
The ISS has been proposed as a simple, reliable, and 
more cost-effective predictor of survival in MM.6,15 Based 
on a collaboration involving investigators from 17 institu-
tions worldwide and data on 11,171 previously untreated 
symptomatic myeloma patients, the ISS separates patients 
into three prognostic groups based on serum ß2-microglobulin 
and albumin levels at the time of starting initial systemic 
therapy (Table 2). The ISS has been validated by geographic 
region, by age (65 years versus 65 years), by standard 
therapy versus autologous SCT, and in comparison with the 
Durie–Salmon and other staging systems.6,16
Prognosis
There is significant variation in the survival of patients with 
MM. Based on the ISS, the median survival of patients 
with stage I, II, or III disease is estimated at 62, 44, and 
29 months, respectively.6 Although serum β2-microglobulin 
and albumin levels combine in the ISS to provide a powerful 
prognostic tool, a number of independent prognostic markers 
have been described that may further assist in predicting 
outcome.17 Many established prognostic markers allowing 
identification of high-risk patients early in the disease course 
have been derived from studies of conventional chemotherapy 
and include age, β2-microglobulin level, World Health 
Organization (WHO) performance status, serum calcium, 
interleukin-6 (IL-6) level, bone marrow plasma cell labeling 
index, and morphological features.18,19 However, in the 
current era of high-dose chemotherapy, novel immunomodu-
latory agents, and new small molecule inhibitors, a number of 
other prognostic markers relating to mechanisms of disease 
progression are now considered to be important.17
Abnormal cytogenetics play a dominant role in predicting 
the outcome of patients with acute leukemia, and the evidence 
now suggests that cytogenetics have a similar role in MM. 
Tricot and colleagues20,21 observed, using standard cytogenetic 
techniques, that in patients with newly diagnosed or previ-
ously treated disease, the presence of partial or complete dele-
tions of chromosome 13 (del13q) and 11q abnormalities were 
associated with inferior event-free survival (EFS) and OS. 
In addition, they noted a significant association between the 
unfavorable karyotypes and immunoglobulin A (IgA) isotype, 
elevated levels of β2-microglobulin, and age 60 years.20
Conventional cytogenetic analysis is hampered by 
low mitotic activity of myeloma cells and may miss up 
to half of chromosome 13 abnormalities. Using FISH, 
Facon and colleagues22 demonstrated that in MM patients 
receiving first-line high-dose chemotherapy, the presence 
of chromosome 13 abnormalities was strongly predictive 
of poor survival, especially when associated with a 
β2-microglobulin level of 2.5 mg/L. FISH has since 
been used to identify patients with poor, intermediate, 
and better prognosis according to immunoglobulin heavy 
chain translocations and chromosome 13 abnormalities 
with other abnormalities such as t(4,14), t(14,16), and 
del17q, emerging as prognostically unfavorable.23 However, 
as combinations of independent prognostic factors provide 
greater power than any one prognostic factor alone, the 
technique with potentially the highest utility in the future 
is gene expression profiling, which allows the simultaneous 
characterization of many different cytogenetic markers.24
Evaluation of response
Evaluation of tumor response to treatment is based on the 
assessment of changes in serum and/or urinary M-protein 
level. The most commonly used criteria for evaluating 
response are those introduced in 1998 by the European Group 
for Blood and Marrow Transplant (EBMT).4 The criteria 
for a complete response (CR) require 5% plasma cells in 
the bone marrow and the complete absence of M-protein 
by immunofixation and electrophoresis, with the response 
maintained for a minimum of six weeks. A partial response 
(PR) is defined as a reduction in serum M-protein levels 
of 50% and a reduction in 24-hour urinary light chain 
excretion either by 90% or to 200 mg, maintained for 
a minimum of six weeks. Near CR (nCR), a subset of PR, 
is defined as a CR with a positive immunofixation test but 
otherwise satisfies the criteria for CR.25 A minimal response 
(MR) is defined as a reduction in serum M-protein levels 
of 25%–49% and a 50%–89% reduction in 24-hour urinary 
light chain excretion that still exceeds 200 mg, maintained 
for a minimum of six weeks.
The International Myeloma Working Group (IMWG) 
has recently proposed changes to the original EBMT criteria 
in order to facilitate precise comparisons between new 
treatment strategies and to provide clarification of response 
in the clinical setting.26,27 For patients with measurable 
levels of serum and urine M-protein, the criteria for CR 
and PR remain unchanged. The most important changes are 
the inclusion of a new category of stringent CR (sCR) to 
reflect recent advances in therapy, and the inclusion of the 
serum-free light chain (FLC) assay to allow evaluation of 
patients with oligosecretory disease. The subcategories of Core Evidence 2009:4 220
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nCR and very good PR (VGPR) have been integrated into 
a single category, VGPR, with sCR defined as CR based on 
EBMT criteria with the additional requirement for a normal 
FLC ratio and the absence of clonal cells in bone marrow 
by immunohistochemistry or immunofluorescence. VGPR 
is defined as serum and urine M-protein levels detectable 
by immunofixation, but not on electrophoresis, or a 90% 
reduction in serum M-protein plus urinary M-protein 
level 100 mg per 24 hours. The IMWG criteria eliminate the 
mandatory six-week period to confirm response and instead 
have a non-time-dependent confirmation for relapse and/or 
disease progression.26 Further modifications to this (including 
the restoration of MR as a response parameter associated with 
clinical benefit) as well as validation of key aspects, such as 
the assessment of serum FLC are anticipated.28
Goals of therapy
Treatment prolongs survival in MM, although remissions 
are inevitably followed by relapse.4 Therefore, the aim of 
treatment includes controlling disease by safely achieving 
a sequence of durable responses, without compromising 
quality of life.29 Given that current assessment techniques 
may not reflect true molecular remission, even using sCR or 
molecular CR criteria, and effective suppression of abnor-
mal karyotype has been linked with long-term survival, 
suppression of abnormal karyotype may represent a part of 
the treatment goal to eradicate the myeloma clone.30 As the 
choice of therapy is influenced by patient factors, such as 
age and comorbidities, the goals of therapy are individual to 
the patient. Thus, CR may be the primary goal in a younger 
patient whereas control of disease activity to prevent pro-
gressive organ damage and to preserve performance status 
may be the goal in an older, more frail patient. The advent 
of novel therapies has dramatically expanded the options 
available for both younger and older patients in this context, 
especially given the favorable tolerability profiles seen with 
newer combinations, including bortezomib-based therapy as 
well as immunomodulatory approaches.
Current therapy options
Treatment recommendations for MM are dynamic and there 
is currently no single standard therapy for active myeloma. 
For patients with asymptomatic disease, a watch-and-wait 
approach is adopted because at present there is no evidence of 
benefit for early treatment in this population.31,32 Patients with 
symptomatic disease involving at least one of the following: 
hypercalcemia, renal insufficiency, anemia, or bone lesions 
require active treatment for which there are multiple options.12 
These include proteasome inhibition (such as bortezomib), 
immunomodulating agents (such as thalidomide and 
lenalidomide), corticosteroids, bisphosphonates,  conventional 
chemotherapy, radiotherapy, and autologous SCT.
Newly diagnosed disease
In patients with newly diagnosed disease who are eligible 
for autologous SCT, the initial goal of treatment is to reduce 
tumor burden with induction therapy. Induction regimens that 
are sufficiently nontoxic to hematopoietic stem cells include 
single-agent dexamethasone, combination vincristine + 
doxorubicin + dexamethasone (VAD), and novel regimens such 
as bortezomib-based treatments, thalidomide + dexamethasone, 
and lenalidomide + dexamethasone.7,27 More recent data sug-
gest VAD has little or no role in induction given its inferiority 
to novel regimens demonstrated in numerous randomized 
trials.27 Following stem cell harvest, high-dose therapy is the 
standard of care for those undergoing autologous SCT given 
its survival advantage over conventional chemotherapy,33 
which may involve a single autologous SCT, tandem autolo-
gous SCT, allogeneic SCT or syngeneic SCT. Interim data 
suggest there is no survival advantage of tandem over single 
autologous SCT, with the latter also being preferred over 
allogeneic SCT due to its superior efficacy in the absence 
of a syngeneic donor, its safety, and the absence of biological 
age-related disease differences.34 However, preliminary 
results for nonmyeloablative allogeneic transplantation are 
encouraging and support the feasibility of this approach.34 
As almost all patients relapse, maintenance treatments that 
help prolong the duration of remission and survival are used, 
including thalidomide.35–37
Patients ineligible for SCT due to their age, performance 
status, comorbidities, or other factors have in the past 
received melphalan plus prednisone as the standard of care 
for induction therapy.38 However, other combinations have 
emerged, with the evidence base, in particular, supporting the 
combination of melphalan, prednisone, and thalidomide27,39 
and most recently melphalan, prednisone, and bortezomib.40 
Indeed, combination approaches with bortezomib as the first 
in class proteosome inhibitor, have shown particular promise 
both in autologous SCT eligible and nontransplantation popu-
lations, with high-quality responses seen.27 Other first-line 
options include melphalan, prednisone, and lenalidomide,41 
lenalidomide plus dexamethasone,42,43 or dexamethasone 
plus thalidomide or bortezomib.39,44 The combination of 
lenalidomide and dexamethasone is now recognized by the 
National Comprehensive Cancer Network (NCCN) practice 
guidelines as an option for primary induction therapy in Core Evidence 2009:4 221
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transplantation candidates based on category of evidence 
2B (lower-level evidence including clinical experience and 
nonuniform consensus),27 together with bortezomib-based 
therapies.27
Relapsed or refractory disease
An ongoing effort toward understanding the molecular 
pathogenesis of MM has led to the rational development of 
novel therapeutic agents, such as the immunomodulatory 
agents thalidomide and lenalidomide, and the proteasome 
inhibitor bortezomib, in this setting. The combination of 
these agents with dexamethasone in particular has shown 
impressive activity in relapsed or refractory MM and adds 
to the wide range of therapeutic options available.45 Other 
options include conventional chemotherapy, melphalan plus 
prednisone, dexamethasone alone in good-risk patients and, 
in patients with early stem cell harvest, autologous SCT may 
be considered as salvage therapy.27
According to NCCN guidelines, patients who relapse 
after more than six months may benefit from reduction 
with the primary induction therapy.27 Conventional 
dose salvage therapy in combination with novel agents 
can be considered in patients with progressive disease 
following allogeneic or autologous SCT, in patients with 
primary progressive disease following initial allogeneic or 
autologous SCT, and in patients who are not candidates 
for transplantation with progressive or relapsing disease. 
Possible salvage therapies with category 1 evidence 
(uniform NCCN consensus based on high-level evidence) 
or 2A (uniform NCCN consensus based on lower-level 
evidence including clinical experience) are summarized in 
Figure 1, together with recommended options for induction 
and maintenance therapies.27 As an example, lenalidomide 
combined with dexamethasone has received US Food and 
Drug Administration (FDA) approval, based on two studies 
of 692 patients, for use in MM patients with at least one 
prior treatment and so is assigned a category 1 recommen-
dation.46 The NCCN recommends anticoagulation therapy 
in patients treated with lenalidomide plus dexamethasone 
with lenalidomide monotherapy as a category 2A 
recommendation.27
Thalidomide
As a salvage therapy for patients with relapsed or refractory 
MM, thalidomide has been investigated as monotherapy, 
in combination with dexamethasone (Thal + Dex), with 
bortezomib and dexamethasone, and in combination with 
dexamethasone, cisplatin, doxorubicin, cyclophosphamide, 
and etoposide.47–49 As a single-agent therapy, thalidomide has 
demonstrated an overall response rate (ORR) approaching 
Induction therapy (+ bisphosphonates and adjunctive therapy)
Maintenance therapy may include the use of steroids, thalidomide, lenalidomide, bortezomib
Stem cell transplant:
• Stem cell harvest
  •  Subsequent auto SCT (single vs double)
    ± maintenance (lenalidomide, thalidomide,
    bortezomib)
• Investigational therapy
  (eg, allogeneic-SCT)
Salvage therapy:
• Repeat primary therapy (if relapse after six months)
• High-dose cyclophosphamide
• Thalidomide ± dexamethasone
• Lenalidomide  ± dexamethasone
• Cyclophosphamide-VAD
• Bortezomib  ± dexamethasone
• Bortezomib + liposomal doxorubicin
• Dexamethasone or DCEP or DT-PACE
Transplant candidates:
• DVD     • Len/DEX
• Dex     • RVD
• Thal/Dex  • Bort/Dex
Nontransplant candidates:
• MP  • Dex
• MPT  • Thal/Dex
• RVD  • Len/Dex
• MP Bort 
Figure 1 Treatment options in multiple myeloma.27
Abbreviations: Bort, bortezomib; Bort/Dex, bortezomib and dexamethasone; DCEP, dexamethasone, cyclophosphamide, etoposide, and cisplatin; Dex, dexamethasone; 
DT-PACE, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide; DvD, liposomal doxorubicin, vincristine, and dexamethasone; Len/Dex, 
lenalidomide plus dexamethasone; MP, melphalan and prednisone; MPT, melphalan, prednisone, and thalidomide; SCT, stem cell transplantation; RvD, lenalidomide, bortezomib 
and dexamethasone;   vAD, vincristine, doxorubicin, and dexamethasone; Thal/Dex, thalidomide plus dexamethasone.Core Evidence 2009:4 222
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30%, with a relatively low CR rate of 1.6%, and an incidence 
of venous thromboembolism (VTE) of 3%, and a rate of 
discontinuation due to intolerance of 15%.50  The combination 
of thalidomide and dexamethasone offers significantly greater 
activity than respective single-agent therapies, with a rate of 
PR or better in the order of 55%–59% (CR 0%–23%), and a 
median survival of 13–26 months in relapsed or refractory 
disease.51–53 Low-dose thalidomide has been investigated in 
combination with cyclophosphamide and dexamethasone, 
yielding an ORR in one study of 79%, including a CR 
rate of 17%.54 Two-year OS and EFS were 73% and 34%, 
respectively.
Bortezomib
Bortezomib was first studied in the setting of relapsed or 
refractory MM, and showed an overall response rate of 28% 
(PR or better) including 10% CR/nCR in heavily pretreated 
patients,25 leading to its accelerated approval by the FDA in 
2003. In a recent systematic analysis, single-agent bortezomib 
was compared with single-agent thalidomide in patients 
with relapsed or refractory MM.55 The ORR was 41% for 
patients receiving bortezomib versus 22% for thalidomide. 
Similarly, bortezomib monotherapy yielded a higher ORR than 
single-agent dexamethasone in the relapse setting (38% vs 18%, 
respectively) and a higher CR rate (6% vs 1%).56 Bortezomib 
was associated with improved TTP compared with single-agent 
dexamethasone (6.2 months vs 3.5 months, respectively) and 
one-year survival (80% vs 66%). A recent update showed 
an ORR of 43% (PR or better) and a median OS of 29.8 
months.57 There is also evidence showing increased response 
rates for bortezomib in combination with dexamethasone.25,58,59 
In combination with low-dose melphalan and dexamethasone, 
bortezomib yielded an ORR of 69%, including 29% with VGPR 
or better.60 The recent FDA approval of a novel bortezomib 
combination with pegylated liposomal doxorubicin was based 
on a priority review of interim data from a phase III clinical trial, 
which showed that this combination significantly extended TTP 
compared with bortezomib alone (9.3 months vs 6.5 months, 
respectively). OS was also significantly improved compared with 
bortezomib alone.61 Bortezomib is currently being investigated 
in the relapsed or refractory disease setting in combination with 
numerous novel agents, including tanespimycin (an inhibitor 
of heat-shock protein 90), perifosine (an AKT inhibitor), and 
oral vorinostat and related histone deacetylase inhibitors.57,62,64,65 
Importantly, a four-drug combination has shown particular 
promise, with a phase I/II trial of bortezomib, melphalan, 
prednisone, and thalidomide yielding an ORR of 67% (all PR), 
including 43% with a VGPR.66
Unmet needs
Corticosteroids and alkylating agents have formed the 
mainstay of therapy for decades and continue to be used in 
combination regimens, where drugs with different mechanisms 
of action can offer important synergistic effects. However, more 
effective targeted therapies are beginning to emerge as a result of 
an improved understanding of the biology of MM.13 The rational 
development of these therapies, which include lenalidomide, 
thalidomide, and bortezomib, provides an opportunity to treat 
patients more effectively with fewer side-effects while aiming 
for durable responses. With mechanisms of action that are 
distinct from cytotoxic chemotherapies, these novel treatments 
(ORR) will continue to offer synergistic effects with conven-
tional treatments and so offer potential survival benefit.
Thalidomide was the first immunomodulatory drug to 
demonstrate significant activity in newly diagnosed and relapsed 
disease, particularly in combination with dexamethasone. Its 
anti-MM effects are directed by multiple mechanisms that 
include antiangiogenesis, immunomodulation of the tumor 
microenvironment, and induction of apoptosis in tumor cells.49 
However, in addition to having teratogenic potential, thalido-
mide is associated with many possible side effects, including 
sedation, fatigue, skin rash, and constipation; less common 
side effects include bradycardia, impotence, neutropenia, 
dysmenorrhea, and edema. Importantly, long term use can cause 
peripheral neuropathy.9 In addition to neuropathy, perhaps the 
most worrying side effect is VTE, including deep vein throm-
bosis (DVT), which is particularly problematic in combina-
tion with multiagent chemotherapy and dexamethasone.67,68
Lenalidomide
As a means of enhancing the immunomodulatory effects and 
overcoming the nonhematological adverse events of thalido-
mide, analogs such as lenalidomide have been developed.9,69 
Like thalidomide, lenalidomide exerts pleiotropic effects, which 
include immunomodulatory, antiangiogenic, and antineoplastic 
activities.69 In preclinical studies, lenalidomide has demonstrated 
more potent anti-MM activity than its parent compound and its 
toxicity profile is more favorable.9,69 After comprehensive phase 
I and phase II trials in advanced MM, followed by two pivotal 
phase III trials, lenalidomide was approved by the US FDA and 
by the European Medicines Agency (EMEA) in June 200770 for 
use in combination with dexamethasone in the treatment of MM 
in patients who have received at least one prior therapy.
Mechanism of action in MM
The molecular mechanisms associated with disease progres-
sion in MM are dependent on the interaction between MM Core Evidence 2009:4 223
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cells and the bone marrow microenvironment.71 Briefly, the 
adhesion of MM cells to bone marrow stromal cells triggers 
the release of cytokines that mediate separate pathways 
of MM cell growth and survival, including proliferation, 
antiapoptosis, cell cycle progression, and migration. 
Stromal cell-derived IL-6, tumor necrosis factor-alpha 
(TNF-α) and vascular endothelial growth factor (VEGF), 
for example, are involved in the activation of several MM 
cell signaling pathways, including phosphatidylinositol 
3-kinase (PI3K)/Akt, Janus kinase (JAK)/signal transducer 
and activator of transcription 3 (STAT3), Raf/Mek/
mitogen-activated protein kinase (MAPK), and NF-κB, 
together with their downstream targets (Figure 2).72
Lenalidomide has been shown to affect many of the 
interactions central to myeloma development by both direct 
and indirect mechanisms.73 The direct effects of lenalido-
mide include induction of apoptosis or cell cycle arrest of 
the tumor cell71,74,75 and indirect effects involving alteration 
of the tumor microenvironment and augmentation of the 
innate and acquired immune responses. Combined, these 
effects result in effective tumor cell reduction and sup-
pression. This duality of action may be important in the 
treatment of MM.76
The rational development of lenalidomide as an 
anticancer agent followed the success of thalidomide, a potent 
inhibitor of TNF-α with antiangiogenesis activity and T-cell 
costimulatory activity.73 Compared with its parent compound, 
lenalidomide is a more powerful inhibitor of TNF-α secretion 
by activated monocytes.77,78 In addition to TNF-α, lenalido-
mide also inhibits transforming growth factor-beta (TGF-β) 
and the proinflammatory cytokines, IL-1β, IL-6, and IL-12, 
whereas secretion of the antiinflammatory cytokine IL-10 
appears to be increased by lenalidomide.78,79 This differential 
regulation of cytokine activity, and particularly IL-6 activity, 
provides the basis for lenalidomide altering the bone mar-
row microenvironment in which the aberrant expression of 
proinflammatory cytokines is important for the growth and 
survival of MM cells.71 Moreover, inhibition of VEGF by 
lenalidomide may alter the bone marrow microvasculature, 
thereby making the tumor microenvironment less hospitable 
for MM cell growth, migration, and survival.71,78 VEGF 
inhibition likely occurs via the PI3K/Akt signaling pathway, 
which normally becomes phosphorylated in response to 
VEGF stimulation.80,81
Lenalidomide is up to 2,000 times more potent than 





































































Figure 2 Pathogenesis of multiple myeloma. Copyright © 2007.   Adapted with permission from Macmillan Publishers Ltd. Hideshima T, Mitsiades C, Tonon G, et al Understanding 
multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–598.
Abbreviations: BAD, BCL-XL associated death promoter; BCL-XL, basal cell lymphoma-extra large; bFGF, basic fibroblast growth factor; BMECs, bone marrow endothelial cells; 
CAMDR, cell adhesion-mediated drug resistance; DKK1, Dickkopf-1; FKHR, forkhead transcription factor; GSK3β, glycogen synthase kinase 3-beta; HGF, hepatocyte growth 
factor; iAP, inhibitor of apoptosis proteins; iCAM, intercellular adhesion molecule; iGF-1, insulin-like growth factor; iL, interleukin; JAK/STAT, janus kinases/signal transducers, and 
activators of transcription; LFA, lymphocyte function-associated antigen; MCL, myeloid cell leukemia; MEK/ERK, mitogen-activated protein kinase/extracellular regulated kinase; 
MiP1α, macrophage inflammatory protein 1alpha; mTOR, mammalian target of rapamycin; MUC, mucin; NFκB, nuclear factor kappa B; OPG, osteoprotegerin; PKC, protein 
kinase C; RANKL, receptor activated NFκB ligand; RUNX, runt-related transcription factor; SDF1α, stromal cell derived factor 1-alpha; TGFβ, transforming growth factor beta; 
TNF-α, tumor necrosis factor-alpha;  vCAM, vascular cell adhesion molecule;   vEGF, vascular endothelial growth factor;   vLA4, very late antigen-4.Core Evidence 2009:4 224
Richardson et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
up to 100 times more potent at increasing the release of IL-2 
and interferon-γ (IFN-γ).77 This T-cell costimulatory activity 
suggests that lenalidomide is able to act as an adjuvant to 
promote type 1 cell-mediated antitumor immune responses 
involving both CD4+ T-helper cells and CD8+ cytotoxic 
T-cells.73 The ability of lenalidomide to enhance activator 
protein-1 and NF-κB activity in antigen-primed T-cells has 
been proposed as a T-cell costimulatory mechanism, which 
may not only overcome T-cell anergy, but also potentiates 
any non-T-cell receptor-mediated signaling.78 In addition to 
bolstering the adaptive immune response, there is also evi-
dence that lenalidomide can enhance innate immunity and 
natural killer cell-mediated lysis of MM cells in particular 
via its effects on IL-2 production by T-cells.71,73,82
Lenalidomide has been shown to directly potenti-
ate apoptosis of MM cells via several pathways. These 
include inhibition of expression of the cellular inhibitor 
of apoptosis protein-2, potentiation of the activities of 
other apoptosis inducers such as TNF-related apoptosis-
inducing ligand (TRAIL), increased sensitivity to Fas 
induction, and enhanced caspase 8 activation.78 Caspase 8, 
an integral component of Fas-mediated apoptosis, is sharply 
upregulated by lenalidomide (Figure 3).63 In addition, dexa-
methasone activates caspase 9 indicating that the two drugs 
in combination generate dual signals capable of enhanced 
cell death.71 Lenalidomide has been associated with direct 
antiproliferative activity against MM cells in the absence 
of immune cells or proapoptotic mechanisms by inducing 
G1 growth arrest.74,78 Importantly, lenalidomide inhibits the 
proliferation of malignant B cells while protecting normal 
CD34+ progenitor cells.75 The various mechanisms of action 
of lenalidomide are summarized in Figure 4.
Clinical evidence for lenalidomide  
in MM
Newly diagnosed disease
Lenalidomide is not yet approved for use in patients with 
previously untreated disease. However, several clinical 
studies have reported promising response and survival out-
comes in this group of patients.
Response rates and duration of response
Lenalidomide plus dexamethasone
In a phase III study, which had a planned enrollment of 
500 patients with newly diagnosed MM but subsequently 
closed after 198 patients were enrolled due to external data 
affecting the acceptability of the control arm, patients were 
randomized to lenalidomide 25 mg/day plus high-dose dexa-
methasone, or high-dose dexamethasone 40 mg/day plus 

















Figure 3 Caspase-mediated pathway. Copyright © 2007. Reproduced with permission by American Society of Hematology. Richardon P, Mitsiades C, Schlossman R, et al. The 
treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007:317–323.
Abbreviations: MM, multiple myeloma; PARP1, Poly(adenine diphosphate-ribose) polymerase 1; Smac, second mitochondria-derived activator of caspase; Caspase, 
cysteine-aspartic acid proteases.Core Evidence 2009:4 225
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three induction cycles, and then 21 of 28 days as maintenance 
thereafter. High-dose dexamethasone was administered on days 
1–4, 9–12, and 17–20 during induction, and then days 1–4 and 
15–18 during maintenance. Treatment with lenalidomide plus 
high-dose dexamethasone yielded an ORR of 85.3% and a CR 
rate of 22.1% versus treatment with high-dose dexamethasone 
alone (51.3% and 3.8%, respectively; P = 0.001).
A second phase III randomized study compared lenalido-
mide plus high-dose dexamethasone with lenalidomide 
plus low-dose dexamethasone in 445 patients with newly 
diagnosed MM.84 Lenalidomide was dosed at 25 mg/day 
on days 1–21 every 28 days. Patients in the high-dose arm 
received dexamethasone 40 mg/day on days 1–4, 9–12, and 
17–20 every 28 days, whereas patients in the low-dose arm 
received dexamethasone 40 mg/day on days 1, 8, 15, and 
22 every 28 days. Within the first four cycles of treatment, 
a response of PR or higher was seen in 82% of patients 
treated with lenalidomide plus high-dose dexamethasone 
versus 70% of patients in the lenalidomide plus low-dose 
dexamethasone arm (P = 0.007). CR plus VGPR rates were 
52% versus 42%, respectively (P = 0.06).
In a phase II study, 34 previously untreated MM patients 
(mean age 64 years) were administered lenalidomide 25 mg/day 
on days 1–21 of a 28-day cycle and dexamethasone 40 mg/day 
on days 1–4, 9–12, and 17–20 of each cycle for at least four 
cycles.42 Treatment with lenalidomide plus dexamethasone 
yielded an TTP of 91%, including six patients (18%) with a 
CR and 13 (38%) who met the criteria for VGPR and nCR.42,43 
Among 21 patients who did not subsequently receive SCT and 
were eligible for treatment beyond four cycles at the discretion 
of the investigator, 14 (67%) achieved either a CR or VGPR.43
Lenalidomide/cyclophosphamide/dexamethasone
A phase II study of 33 patients (median age 63 years) 
with newly diagnosed MM evaluated the combination of 
lenalidomide 25 mg/day on days 1–28 of every 28-day cycle, 
cyclophosphamide 300 mg/m2 on days 1, 8, and 15 of each 
cycle, and dexamethasone 40 mg/day on days 1, 8, 15, and 
22 of each cycle.85 Among 19 of 33 evaluable patients, two 
achieved a VGPR (10.5%) and 13 achieved a PR (68.4%), 
giving an ORR of 78.9%.
Lenalidomide/bortezomib/dexamethasone (Rvd)
In a phase I/II study, the combination of lenalidomide 
15–25 mg/day on days 1–14, bortezomib 1.0–1.3 mg/m2 on 
days 1, 4, 8, and 11, and dexamethasone 40/20 mg/day (cycles 
1–4/5–8) on day of and day after bortezomib administration 
for up to eight 21-day cycles produced an ORR of 98% 
in 42 evaluable patients with newly-diagnosed MM.86 
Nine of 42 (21%) patients had a CR, 3 (7%) had nCR, 
10 (24%) had VGPR, and 19 (45%) had PR, giving an 
ORR of 98% at the time of this analysis. All 11 patients 
who received treatment with lenalidomide/bortezomib/
dexamethasone RVd at the phase II dose level of lenalidomide 
25 mg, bortezomib 1.3 mg, and dexamethasone 20 mg 
achieved PR or better (100% ORR).




























Figure 4 Mechanism of action of lenalidomide in multiple myeloma. Copyright © 2009.   Adapted with permission from Richardson P, Jagannanth S, Hussein M, et al. Safety and 
efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009;114:772–778.
Abbreviations: bFGF, basic fibroblast growth factor; CTL, cytotoxic T lymphocytes; NK, natural killer cells;   VEGF, vascular endothelial growth factor. Core Evidence 2009:4 226
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Clarithromycin/lenalidomide/dexamethasone (BiRD)
In a phase II study of 72 patients (median age 63 years) with 
newly diagnosed MM, induction therapy with clarithromycin 
500 mg twice -daily, lenalidomide 25 mg/day on days 1–21 of 
a 28-day cycle, and dexamethasone 40 mg/day once weekly 
was associated with an objective response of PR or better in 
65 (90.3%) patients (90.3%), including a CR rate of 38.9%.87 
Fifty-three patients (73.6%) achieved at least a 90% decrease 
in M-protein levels. The mean duration of response was 333 
days and the mean time to response was 54 days, with a 
mean time to maximum response of 209 days. Patients with 
atypical serum immunofixation pattern (ASIP) development 
during induction therapy with BiRD had significantly better 
response than patients without ASIP, with a CR rate of 71% 
versus 23%, respectively (P = 0.00002).88
Lenalidomide/melphalan/prednisone (RMP)
In a phase I/II study conducted by the Italian Multiple 
Myeloma Network, nine monthly cycles of lenalidomide 
5–10 mg/day administered on days 1–21, melphalan 
0.18–0.25 mg/kg given on days 1–4, and prednisone 2 mg/kg 
given on days 1–4 yielded an ORR of 81% in 53 elderly 
patients (median age 71 years) with newly diagnosed 
MM.41 Seven patients (13%) in total had a CR, including 
5 of 21 (24%) patients assigned to lenalidomide 10 mg plus 
melphalan 0.18 mg/kg, and 2 (10%) of 20 (10%) patients 
assigned to lenalidomide 10 mg plus melphalan 0.25 mg/kg. 
Another 13 patients (25%) in total had a VGPR. The median 
time to best response was four months and PR was achieved 
in 53% of patients after the first cycle of treatment.
Time to progression
Lenalidomide plus dexamethasone
In a phase II study, lenalidomide plus dexamethasone was asso-
ciated with a median TTP of 32.4 months in patients who did not 
undergo SCT, whereas median TTP was not reached at the time 
of publication in patients who underwent SCT.43 The two-year 
TTP rates were 71% for the entire cohort, 66% in the nontrans-
plantation group, and 83% in the transplantation group.
Rvd
In a phase I/II study, median TTP was not reached after 
a median follow-up of four months in 42 patients who 
received lenalidomide in combination with bortezomib and 
dexamethasone.86
RMP
Among 21 elderly patients (median age 69 years) in a 
phase I/II study who received the maximum tolerated 
dose of lenalidomide 10 mg/day for 21 days, melphalan 
0.18 mg/kg for four days, and prednisone 2 mg/kg for 
four days of every 28 days for a maximum of nine cycles, 
followed by lenalidomide 10 mg/day for 21 of every 28 days 
as maintenance after a median follow-up of 29.5 months. The 
median TTP was 28.5 months.89
Overall survival
Lenalidomide plus dexamethasone
In a phase III study comparing lenalidomide in combina-
tion with either high-dose or low-dose dexamethasone, OS 
was superior for the low-dose dexamethasone combination 
(P = 0.006).84
Rvd
In a phase I/II study, median OS was not reached after a 
median follow-up of four months.86
BiRD
Among 72 evaluable patients treated with BiRD in a phase II 
study, actuarial EFS at two years was 97.2%.87 The median 
EFS duration was not yet reached.
One-, two-, and three-year survival
Lenalidomide plus dexamethasone
Lenalidomide plus dexamethasone has recently been evaluated 
in a randomized controlled phase III study of 445 patients 
with previously untreated MM.84,90 Survival significantly 
favored lenalidomide plus low-dose dexamethasone, with 
a one-year survival rate of 96% compared with 88% for 
lenalidomide plus high-dose dexamethasone (P = 0.006).84 
Among patients aged 65 years, one-year survival rates for 
low- versus high-dose dexamethasone were 97% versus 92%, 
respectively (P = 0.022); the respective data for patients 
aged 65 years were 94% versus 83% (P = 0.002).90 Two-year 
OS rates were 87% versus 75%, respectively.84 In a land-
mark analysis of the 210 patients who were alive and went 
off study after four months, the one- and two-year OS rates 
among the 102 patients who underwent SCT were 99% and 
94%, respectively. In contrast, among the 108 patients who 
did not undergo SCT, one- and two-year OS rates were 85% 
and 70%, respectively.
In a second randomized controlled phase III study, 
one-year OS rates were 93% and 91% in patients assigned 
to lenalidomide plus high-dose dexamethasone and high-
dose dexamethasone alone, respectively.83 In a subgroup 
analysis that considered patients with and without abnormal 
karyotypes at baseline, one-year OS rates among those with 
abnormal karyotypes were 82% and 77% in patients treated Core Evidence 2009:4 227
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with lenalidomide plus high-dose dexamethasone and 
dexamethasone alone, respectively.91
Among a cohort of 34 patients treated with lenalidomide 
plus dexamethasone in a phase II study, two- and three-year 
OS was approximately 91% and 88%, respectively.43
RMP
Among 53 elderly patients treated with RMP in a phase II 
study, the one-year OS rate was 100%.41 Among 21 patients 
treated with the maximum tolerated dose in this study 
followed by lenalidomide 10 mg/day on 21 of every 28 days 
as maintenance therapy, the two-year OS rate was 90.5%.92
Adverse events
Lenalidomide plus dexamethasone
A phase III study conducted by the Eastern Cooperative 
Oncology Group (ECOG) reported a lower rate of grade 
3 or 4 adverse events among patients who were random-
ized to lenalidomide plus low-dose dexamethasone than 
in patients randomized to lenalidomide plus high-dose 
dexamethasone.90 In patients assigned to high- versus 
low-dose dexamethasone, major grade 3 or 4 toxicities 
and their respective rates were: neutropenia (10% vs 19%, 
respectively; P = 0.01); VTE (25% vs 9%; P  0.001); and 
infection/pneumonia (16% vs 6%; P  0.001). Grade 3 or 4 
nonhematological toxicities occurred in 49% and 32% of 
patients assigned to high- versus low-dose dexamethasone, 
respectively in combination with lenalidomide (P  0.001). 
Of verified deaths in the high-dose dexamethasone arm, 13 
were due to disease progression, six cases were related to 
VTE, three were due to infection, and another five cases 
were due to cardiac ischemia, stroke, and respiratory failure. 
Of nine verified deaths in the low-dose dexamethasone arm, 
five were due to disease progression, two to infection, one 
to VTE, and one to cardiac arrest. In the first four months 
of therapy, the mortality rate was 5% in the high-dose 
dexamethasone group compared with 0.5% in the low-dose 
group.
In a second randomized, double-blind, phase III study, 
lenalidomide plus high-dose dexamethasone was associated 
with a higher rate of adverse events than treatment with 
high-dose dexamethasone alone.83 Grade 3 or 4 neutropenia 
was reported by 13.5% of patients treated with lenalido-
mide plus high-dose dexamethasone compared with 2.4% 
of patients treated with high-dose dexamethasone alone 
(P = 0.01). There were 20 VTE events in the lenalidomide 
plus dexamethasone group including 14 events associated 
with aspirin prophylaxis; there were 12 thromboembolic 
events in the dexamethasone-only group all of which were 
associated with aspirin prophylaxis.
In phase II studies of lenalidomide plus dexamethasone, 
47%–55% of patients experienced a grade 3 or 4 nonhema-
tological toxicity during therapy, most commonly fatigue 
(15%–21%), anxiety (6%), pneumonitis (6%), muscle 
weakness (6%), and rash (6%).42,43 Grade 3 or 4 hemato-
logical adverse events included neutropenia (12%–21%), 
leucopenia (9%), lymphopenia (6%), and anemia (6%). All 
patients received aspirin once daily as thromboprophylaxis. 
However, although one patient developed a grade 4 pulmo-
nary embolism they recovered with therapy. Two patients 
died from infection that was deemed to be possibly related 
to study therapy.42,43
Rvd
In a phase I/II dose-finding study, among 53 evaluable 
patients who completed a median of six treatment cycles, 
14 patients discontinued treatment.86 Two dose-limiting 
toxicities of grade 3 hyperglycemia due to high-dose dexa-
methasone were seen at dose level 4 (lenalidomide 25 mg/day, 
bortezomib 1.3 mg/m2, and dexamethasone 40 mg/day), with 
subsequent recruitment into phase II involving a reduction 
in dexamethasone dose to 20 mg/day. Dose reductions in 
cycle 2 and beyond occurred for lenalidomide in 12 patients, 
bortezomib in 11 patients, and dexamethasone in 18 patients. 
Adverse events were manageable with no unexpected events, 
no grade 4 peripheral neuropathy, two episodes of DVT, and 
no treatment-related mortality.
BiRD
In a phase II study, 17 of 72 patients treated with BiRD 
required at least one lenalidomide dose reduction for a 
grade 3 or 4 adverse event.87 Grade 3 or 4 hematological 
toxicities included neutropenia (19.4%), anemia (13.8%), and 
thrombocytopenia (22.2%). Nonhematological grade 3 or 4 
toxicities included myopathy (11.1%), thrombosis (9.7%), 
rash (5.6%), and diverticular abscess (5.6%). VTE occurred 
in nine patients (12.5%), of which five events were associated 
with aspirin interruption or poor compliance.87
RMP
In a phase II study of RMP in 53 elderly patients, at the 
maximum tolerated dose, grade 3 or 4 hematological tox-
icities were neutropenia (52%), thrombocytopenia (24%), 
and anemia (5%).41 Grade 3 febrile neutropenia, vasculitis, 
and VTE were reported in 10%, 10%, and 5% of patients, 
respectively. In a subgroup of 21 patients who were followed 
for a median of 29.5 months, grade 3 and 4 neutropenia Core Evidence 2009:4 228
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were reported in 38% and 14% of patients, respectively, 
during initial therapy.92 Grade 3 and 4 thrombocytopenia 
were reported in 14% and 10% of patients, respectively. 
Whereas the incidence and depth of neutropenia did not 
increase with the number of cycles, thrombocytopenia was 
more pronounced after nine cycles. One patient required 
a lenalidomide dose reduction for severe neutropenia and 





In MM patients who received initial therapy with 
lenalidomide plus dexamethasone, a retrospective analysis 
of a five-year treatment period at a single institution 
indicated there was a trend towards decreased peripheral 
blood stem cell yield with increasing duration of lenalido-
mide therapy.93 A retrospective study by Paripati and 
colleagues comparing lenalidomide plus dexamethasone 
induction therapy versus other induction therapy showed 
that the first attempt at stem cell collection was unsuccessful 
significantly more frequently in lenalidomide plus 
dexamethasone recipients compared with those who had 
received other induction therapy (7% vs 45%, respectively; 
P = 0.001).94 Lenalidomide plus dexamethasone recipi-
ents had lower mean peripheral blood CD34+ cell counts 
compared with those who received other induction therapies 
(14.0 cells/µL vs 28.9 cells/µL; P  0.0002) and mean total 
stem cells collected (5.1 × 106 cells/kg vs 7.4 × 106 cells/kg; 
P = 0.0025) compared with those who received other induc-
tion therapies. However, compared with single-agent 
dexamethasone, thalidomide plus dexamethasone or 
vincristine/adriamycin/dexamethasone, there was no effect 
on quality of yield in patients receiving lenalidomide based 
on similar engraftment.93
Lenalidomide-based induction therapy
In a recent study where 21 patients with MM received 
lenalidomide-based induction therapy prior to stem cell mobi-
lization, lenalidomide did not prevent the harvest of adequate 
numbers of CD34+ cells for autologous SCT (median 6.3 
cells × 106/kg; range 2.4–19.7 cells × 106/kg).95 Patients were 
mobilized with cyclophosphamide plus granulocyte colony-
stimulating factor (G-CSF) (n = 17), G-CSF and AMD3100 
(n = 2), or G-CSF alone (n = 2). Repeat mobilization 
was required in patients who received G-CSF alone and 
was successful on the second attempt with the addition 
of AMD3100. The median number of collections was 3 
(range 1–8) in patients mobilized with cyclophosphamide 
plus G-CSF and 4.5 (range 2–6) in those mobilized with 
G-CSF plus AMD3100. The respective median CD34+ 
cell counts were 6.3 × 106/kg (range 3.0–19.7 × 106/kg) 
and 8.4 × 106/kg (range 5.6–12.3 × 106/kg). No correlation 
between the number of lenalidomide cycles (median 4, 
range 1–16) and the number of stem cell collections or total 
CD34+ cell counts was reported.
BiRD plus G-CSF or G-CSF plus cyclophosphamide 
for stem cell mobilization
In a subset of 28 treatment-naïve MM patients who were 
treated with the BiRD regimen in a phase II trial, the 
effect of cyclophosphamide plus G-CSF as a stem cell 
mobilization regimen compared with G-CSF alone was 
investigated.96 Successful stem cell harvest sufficient for 
two autologous SCTs was achieved in all patients who 
received mobilization with cyclophosphamide plus G-CSF, 
compared with only 33% of patients who were mobilized 
with G-CSF alone (P  0.0001). No correlation between 




by lenalidomide and prednisone
In a phase II study, 94 patients aged 65–75 years with newly 
diagnosed MM were treated with bortezomib and doxoru-
bicin plus dexamethasone (PAD) induction (bortezomib 
1.3 mg/m2 on days 1, 4, 8, and 11, pegylated liposomal 
doxrorubicin 20 mg/m2 on day 4, and dexamethasone 40 
mg on days 1–4, 8–11, and 15–18 for cycle 1 and days 1–4 
for cycles 2–4) prior to reduced intensity autologous SCT.89 
Cyclophosphamide 3 mg/m2 plus G-CSF was used to har-
vest stem cells, with patients then conditioned with tandem 
melphalan 100 mg/m2 and stem cell support (MEL100). 
Following autologous SCT, patients received consolidation 
therapy with lenalidomide 25 mg/day on days 1–21 plus 
prednisone 50 mg/day every other day, and then maintenance 
therapy with lenalidomide alone (10 mg/day on days 
1–21 every 28 days). After four cycles of PAD therapy, 96% 
of patients had at least PR (60% had at least VGPR, 23% 
had at least nCR, and 13% had CR), after tandem MEL100, 
95% had at least PR (80% at least VGPR, 60% at least nCR, 
and 33% had CR), and after lenalidomide plus prednisone 
consolidation all patients had at least PR (89% had at least 
VGPR, 78% had at least nCR, and 56% had CR).Core Evidence 2009:4 229
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Adverse events
Lenalidomide plus prednisone consolidation therapy
In a study of 94 elderly patients with newly diagnosed MM 
who received lenalidomide plus prednisone as consolidation 
therapy following PAD induction therapy and autologous 
SCT, one case of DVT and one discontinuation because of 
prolonged thrombocytopenia and anemia were reported dur-
ing consolidation therapy.89
Relapsed or refractory disease
Two multicenter, double-blind, randomized, placebo-
controlled phase III studies (MM-009/ and MM-010) 
investigated the efficacy and safety of lenalidomide plus 
dexamethasone versus dexamethasone alone in the treatment 
of patients with relapsed or refractory MM; they provided 
the basis for the approval of lenalidomide in this indication.46 
Patients with relapsed or refractory MM and 3 previous 
regimens were eligible. Based on the findings of phase I and II 
studies, lenalidomide was administered at 25 mg/day on 
days 1–21 of each 28-day cycle. Patients were randomized 
to either four 28-day cycles of lenalidomide plus high-dose 
dexamethasone 40 mg/day on days 1–4, 9–12, and 17–20 of 
each cycle, or matched placebo plus dexamethasone as for 
the group assigned to active treatment. After four cycles of 
therapy, treatment was continued until disease progression, 
but with dexamethasone 40 mg administered only on days 
1–4 of every 28-day cycle. The primary end point of TTP was 
evaluated according to EBMT criteria.4 A total of 353 patients 
in MM-009 and 351 patients in MM-010 were randomized 
and received study medication.
Response rates and duration of response
Lenalidomide plus dexamethasone
In the MM-009 and MM-010 studies, lenalidomide in 
combination with high-dose dexamethasone led to a signifi-
cantly better ORR compared with dexamethasone alone.2,3 
In these studies, 108 patients (61.0%) in MM-009 and 
106 patients (60.2%) in MM-010 assigned to lenalidomide 
plus dexamethasone achieved a response of PR or better. 
In comparison, 35 patients (19.9%) in MM-009 and 42 patients 
(24.0%) in MM-010 assigned to dexamethasone alone had 
a response to therapy (P  0.001 versus lenalidomide plus 
dexamethasone). In both studies, the CR rate in response 
to lenalidomide plus dexamethasone was approximately 
15% (MM-009: 14.1%; MM-010: 15.9%) and the nCR rate 
was approximately 9% (MM-009: 10.2%; MM-010: 8.5%) 
(Table 3).2,3 In a pooled analysis that included data from all 
704 patients enrolled in both trials, the ORR in the lenalido-
mide plus dexamethasone group and the dexamethasone-only 
group was 60.6% and 21.9%, respectively (P  0.001).97 
The respective data for CR rate were 15.0% and 2.0% 
(P  0.001). Among patients who received lenalidomide 
plus dexamethasone, the median duration of response was 
significantly higher for those who achieved a CR or nCR 
compared with those who achieved a PR (not yet reached vs 
8.8 months; P  0.001).98
Patients in the MM-009 and MM-010 studies were stratified 
according to β2-microglobulin (2.5 mg/L vs 2.5 mg/L), 
prior SCT (none vs 1), and number of prior regimens 
(1 vs 1).2,3 In both studies lenalidomide plus dexamethasone 
was associated with significantly higher response rates than 
dexamethasone alone, irrespective of β2-microglobulin 
level, prior SCT, or number of prior therapies (Table 4). 
In addition, lenalidomide plus dexamethasone yielded higher 
response rates than dexamethasone alone irrespective of prior 
bortezomib or thalidomide therapy.2,3
In a prospective, pooled subgroup analysis of 704 patients 
enrolled in the MM-009/ and MM-010 studies, the ORR was 
significantly higher with lenalidomide plus dexamethasone 
treatment compared with dexamethasone alone in patients 
who had received prior thalidomide (60% vs 18%, 
respectively; P  0.01) or in patients who had not had prior 
Table 3 Treatment response, time to progression and overall survival in MM-009 and MM-0102,3
MM-009 (N = 353) MM-010 (N = 351)
Leni + Dex Dex P value Leni + Dex Dex P value
Randomized, n 177 176 176 175
ORR (CR, nCR, PR), % 61.0 19.9 0.001 60.2 24.0 0.001
CR, % 14.1 0.6 0.001 15.9 3.4 0.001
Median TTP, months 11.1 4.7 0.001 11.3 4.7 0.001
Median OS, months 29.6 20.2 0.001 NR 20.6 0.03
Abbreviations: CR, complete response; Dex, placebo plus dexamethasone; Leni + Dex, lenalidomide plus dexamethasone; nCR, near complete response; NR, not reached; 
ORR, overall response rate; OS, overall survival; PR, partial response;   TTP, time-to-progression.Core Evidence 2009:4 230
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thalidomide (64% vs 28%; P  0.01).99 When patients 
who had received prior thalidomide were divided into three 
subgroups based on the degree of thalidomide resistance, 
the ORR was similar across resistance groups. Even the 
group with the strongest resistance to thalidomide (ie, never 
responded nor had stable disease) had a higher response rate 
(P  0.01).
In another prospective subgroup analysis, the benefits 
of starting lenalidomide therapy at first relapse were 
assessed by comparing outcomes with lenalidomide 
plus dexamethasone versus dexamethasone alone among 
patients who had received one versus 2 prior therapies.100 
Among the 248 of 692 patients who had received only one 
prior therapy, those assigned to second-line lenalidomide 
plus dexamethasone had a significantly higher ORR than 
those receiving dexamethasone alone (65% vs 26%, 
respectively). Among the 456 patients who had received 2 
prior therapies, those treated with lenalidomide plus 
dexamethasone also had a significantly higher ORR 
than those treated with dexamethasone alone (58% vs 
20%, respectively). Comparing patients who received 
lenalidomide plus dexamethasone as second-line versus 
later salvage therapy, the ORR appeared higher with 
early treatment. A higher proportion of patients receiving 
second-line therapy had previously had SCT (66% vs 54%), 
whereas more patients receiving later salvage therapy had 
previously received thalidomide (53.2% vs 12.5%) and 
bortezomib (11.6% vs 0.4%).
Table 4 Treatment outcomes in MM-009 and MM-010: subgroup analyses2,3
Subgroup analysis MM-009 (N = 353) MM-010 (N = 351)
Leni + Dex Dex P value Leni + Dex Dex P value
Number of prior therapies
    1 prior therapy
    ORR, % 64.7 22.4 0.001 66.1 29.8 0.001
    Median TTP, months NR 5.1 0.001 NR 4.7 0.001
    ≥2 prior therapies
    ORR, % 58.7 18.3 0.001 57.5 21.2 0.001
    Median TTP, months 10.2 4.6 0.001 11.1 4.7 0.001
Prior therapies
    Prior thalidomide
    ORR, % 56.8 12.5 0.001 49.1 16.4 0.002
    Median TTP, months 8.5 4.1 0.001 8.4 4.6 0.001
    No prior thalidomide
    ORR, % 64.1 26.0 0.001 65.0 28.7 0.001
  Prior bortezomib
    ORR, % 68.4 10.0 0.001
    Median TTP, months 10.3 3.3 0.001
    No prior bortezomib
    ORR, % 60.1 21.2 0.001
β2-microglobulin level
    2.5 mg/L
    ORR, % 75.0 27.5 0.001 70.6 37.5 0.001
    2.5 mg/L
    ORR, % 55.2 16.8 0.001 56.0 18.9 0.001
Prior SCT
    Yes
    ORR, % 66.1 19.4 0.001 61.9 28.4 0.001
    No
    ORR, % 52.9 20.6 0.001 58.2 18.8 0.001
Abbreviations: Dex, placebo plus dexamethasone; Leni + Dex, lenalidomide plus dexamethasone; NR, not reached; ORR, overall response rate; SCT, stem cell transplantation; 
TTP, time to progression.Core Evidence 2009:4 231
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In further subanalyses of MM-009 and MM-010, Foa 
and colleagues reported that among 154 patients with 
IgA disease at baseline, lenalidomide plus dexametha-
sone was associated with a significantly higher ORR than 
dexamethasone alone (68.1% vs 18.3%, respectively; 
P  0.001).101 The CR rate in patients with IgA disease 
who were treated with lenalidomide plus dexamethasone, 
versus dexamethasone alone, was 18.1% and 0%, respec-
tively (P = ns). Similarly, in patients without IgA disease at 
baseline, lenalidomide plus dexamethasone achieved a higher 
ORR compared with dexamethasone alone (57.7% vs 23.0%, 
respectively; P  0.001). A separate analysis demonstrated 
that the superiority of lenalidomide plus dexamethasone 
compared with dexamethasone alone was independent of 
baseline ECOG performance status.102 In this analysis, 
patients with an ECOG scores of 0 or 1 had significantly 
higher ORR with lenalidomide plus dexamethasone (59% 
and 62%, respectively) compared with dexamethasone 
alone (22% and 22%, respectively; P  0.001 for both). 
Also, age did not determine response to lenalidomide, with 
another subanalysis showing that ORR was significantly 
higher for lenalidomide plus dexamethasone compared 
with dexamethasone alone for patients aged 65 years 
(61.5% vs 22.2%, respectively), 65–75 years (58.4% vs 
21.4%), and 75 years (63.9% vs 29.9%).103
In a pooled subgroup analysis of 682 patients with serum 
creatinine levels of 2.5 mg/dL at baseline, lenalidomide 
plus dexamethasone significantly improved response rate 
compared with dexamethasone alone in patients with normal 
renal function (creatinine clearance [CrCl]  80 mL/min: 
63.9% vs 27.0%, respectively; P  0.001) and in those with 
mild (CrCl  50 mL/min to 80 mL/min: 64.0% vs 19.8%; 
P  0.001) and moderate (CrCl  30 mL/min to 50 mL/min: 
61.9% vs 20.6%; P = 0.001) renal impairment104 (Table 5). 
The ORR was not significantly different between lenalido-
mide plus dexamethasone and dexamethasone alone in the 
28 patients with severe renal impairment (CrCl 30 mL/min: 
50.0% vs 25.0%, respectively; P = 0.205), with CR rates 
following a similar trend to ORR.
Finally, a post-hoc analysis of data from the MM-009 and 
MM-010 trials indicated that dexamethasone dose reductions 
improved the efficacy of lenalidomide plus dexamethasone 
treatment compared with patients who continued to receive 
dexamethasone at the planned dose.105 Patients assigned to 
lenalidomide plus dexamethasone and who had a subsequent 
dexamethasone dose reduction experienced a significantly 
higher ORR and CR rate (69.6% and 23.9%, respectively) 
compared with patients who continued to receive the standard 
dexamethasone regimen in combination with lenalidomide 
(50.8% and 13.0%, respectively; P  0.05 for both).
In an ongoing Dutch compassionate need program, 
patients with relapsed or refractory MM were treated with 
lenalidomide 25 mg/day on days 1–21 every 28 days, in 
combination with dexamethasone 40 mg/day on days 1–4 and 
15–18 until disease progression, unacceptable toxicity, or 
for a maximum of eight courses. Fifteen patients received 
lenalidomide 10 mg/day maintenance therapy without dexa-
methasone after 6–8 courses of therapy.106 The preliminary 
response data of the first 42 patients showed an ORR of 83% 
(CR 5%, VGPR 45%, PR 45%, and MR 5%).
Single-agent lenalidomide
In a multicenter, open-label phase II study of single-agent 
lenalidomide in relapsed or refractory MM, 102 patients were 
treated with either lenalidomide 30 mg once daily or 15 mg 
twice daily for 21 days of every 28-day cycle.107 A total 
of 56% of patients had received at least four prior lines of 
Table 5 Treatment response, time-to-progression and over-
all survival in MM-009 and MM-010: pooled subgroup analysis 
according to baseline renal impairment104
MM-009 and MM-010 (N = 682)
Leni + Dex Dex P value
CRCl  80 mL/min
  ORR, % 63.9 27.0 0.001
  CR, % 16.5 1.8
  Median TTP, months 11.3 4.7 0.001
  Median OS, months NR 101.2 0.142
CRCl  50 to 80 mL/min
  ORR, % 64.0 19.8 0.001
  CR, % 12.8 2.3
  Median TTP, months 12.1 4.7 0.001
  Median OS, months 34.7 27.2 0.131
CRCl  30 to 50 mL/min
  ORR, % 61.9 20.6 0.001
  CR, % 21.4 0
  Median TTP, months 11.4 2.8 0.001
  Median OS, months 30.4 12.5 0.068
CRCl  30 mL/min
  ORR, % 50.0 25.0 0.205
  CR, % 6.3 8.3
  Median TTP, months 7.9 4.7 0.031
  Median OS, months 18.6 16.9 0.849
Abbreviations: CR, complete response; CRCl, creatinine clearance; Dex, placebo 
plus dexamethasone; Leni + Dex, lenalidomide plus dexamethasone; NR, not reached; 
ORR, overall response rate.Core Evidence 2009:4 232
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therapy, 61% had received prior high-dose chemotherapy 
followed by SCT, 76% had received prior thalidomide, 
and 18% had previously received bortezomib. In the entire 
cohort, the ORR to lenalidomide was 25% (24% for once 
daily and 29% for twice daily), and a further 29% of patients 
responded with the addition of low-dose dexamethasone, 
which was permitted after two cycles for progressive or 
stable disease. The median duration of response, with 
censoring at the time that dexamethasone was added, was 
19 months (range 2–22 months). In the twice-daily group, the 
median duration of response was 23 months (2–25 months). 
In a long-term follow-up of 15 patients who remained on 
therapy for a median of 4.1 years, 11 had achieved either 
CR or PR and continued to respond, including four of six 
patients receiving lenalidomide monotherapy (including a 
patient who progressed after 3.7 years), and seven of nine 
patients receiving concomitant dexamethasone.108 The 
remaining four patients maintained stable disease during 
this long-term follow-up.
A second multicenter, open-label study evaluated single-
agent lenalidomide in 222 patients with relapsed or refractory 
MM (MM-014).111,112 Lenalidomide was administered at 
30 mg once daily on days 1–21 every 28 days until disease 
progression or intolerance. Concomitant dexamethasone was 
not permitted. All patients had received at least two prior 
therapies, including bortezomib (43%), thalidomide (80%), 
and stem cell transplantation (45%). The ORR was 26%, with 
an additional 66% of patients achieving stable disease. The 
median duration of response was 13 months.
In a phase I dose-escalation study of 27 patients who 
received lenalidomide as a single daily dose, 24 patients 
received at least 28 days of therapy and were considered 
evaluable for response.113 Seventeen patients (71%) had a 
best response of 25% reduction in M-protein, including 
seven patients (29%) who achieved 50% reduction. The 
median duration of response was six months and the median 
time to response was two months.
Lenalidomide plus doxorubicin
In the relapsed or refractory MM setting, lenalidomide has 
been investigated in a phase I/II study in combination with 
pegylated liposomal doxorubicin-based chemotherapy.114 
Sixty-two patients (median age 62 years) received liposomal 
doxorubicin 40 mg/m2 and vincristine 2 mg on day 1, 
dexamethasone 40 mg/day on days 1–4, and lenalidomide 
5–15 mg/day on days 1–21 of every 28-day cycle. Among 
52 evaluable patients, the ORR of the combination was 
75%, including 29% of patients with either a CR or nCR. 
Best response occurred after a median of 115 days and four 
cycles of therapy.
Lenalidomide/cyclophosphamide/dexamethasone
In a retrospective analysis of 21 patients who were adminis-
tered lenalidomide 25 mg/day on days 1–21, cyclophospha-
mide 500 mg/day on days 1, 8, 15, and 21, and dexamethasone 
40 mg/day on days 1–4 and 12–15 of every 28-day cycle for 
a maximum of nine cycles, 15 of 20 (75%) evaluable patients 
had a response, including one CR, three VGPR, and nine 
PR.115 The median time to response was 31 days. There was 
no difference in response rate between patients who required 
a dose reduction compared with those who tolerated the full 
treatment schedule.
Lenalidomide/doxorubicin/dexamethasone (RAD)
In a phase I/II study, lenalidomide was evaluated in combi-
nation with doxorubicin and dexamethasone.116,117 A total 
of 69 patients (median age 65 years) received six 28-day 
cycles of lenalidomide 10–25 mg/day on days 1–21, doxo-
rubicin 4–9 mg/m2 as a 24-hour infusion on days 1–4, and 
dexamethasone 40 mg/day on days 1–4 and 17–20, including 
20 patients who received treatment at five lenalidomide and 
doxorubicin dose levels during phase I. In phase II of the 
study, all patients received the fifth dose level of lenalido-
mide 25 mg on days 1–21, doxorubicin 9 mg/m2 on days 
1–4, and dexamethasone 40 mg on days 1–4 and 17–20.117 
G-CSF support was given at 6 mg on day 6. ORR for patients 
receiving treatment at dose levels 1–4 in the phase I study 
was 60%, including five patients (25%) with nCR. ORR for 
the 41 patients receiving the highest dose level in phase II 
of the study was 85%, including 10 patients (24%) with CR 
and 24 patients (59%) with VGPR.
Lenalidomide plus prednisone
In a study of 69 patients who received lenalidomide plus 
corticosteroids (pulsed dexamethasone or prednisone) as 
part of an Expanded Access Program in Canada, the ORR 
was 58% in patients aged 65 years and older, and 56% in 
patients aged 65 years.118
Lenalidomide plus bortezomib
In the relapsed or refractory disease setting, the combination 
of lenalidomide and bortezomib in a phase I dose-escalation 
study of 36 patients yielded an ORR of 58%, including 6% 
with CR or nCR.110 Lenalidomide was administered at a dose 
of 5, 10, 15, or 20 mg on days 1–14, and bortezomib was given 
at either 1.0 or 1.3 mg/m2 on days 1, 4, 8, and 11 of every 
21-day cycle for a median of six cycles. The median duration Core Evidence 2009:4 233
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of response was six months, with 11 patients remaining 
on therapy beyond one year. Dexamethasone was added 
in 14 patients with progressive disease, with an objective 
response subsequently achieved in 10 patients.
Rvd
Lenalidomide may sensitize MM cells to bortezomib and 
dexamethasone, suggesting combination therapy may 
enhance clinical activity. In a recently completed phase 
II trial of 65 patients, 43 patients (median age 67 years) 
with relapsed or refractory MM have to date received up 
to eight cycles of lenalidomide 15 mg on days 1–14 of a 
21-day cycle, bortezomib 1.0 mg/m2 on days 1, 4, 8, and 
11 of a 21-day cycle, and dexamethasone 40 mg (cycles 
1–4) or 20 mg (cycles 5–8) twice weekly for two weeks of 
every 21-day cycle.62,119 Based on safety data, dexametha-
sone dosing was subsequently reduced to 20 mg for cycles 
1–4 and 10 mg for cycles 5–8. In 33 evaluable patients with 
a median of two prior therapies including dexamethasone 
(90%), thalidomide (78%), and bortezomib (68%), the 
ORR (minimal response or better) of major response or 
better was 73%, including 36% with CR, unconfirmed 
CR or VGPR. The median duration of response was 
39 weeks.119
Terpos and colleagues compared lenalidomide 25 mg/day 
on days 1–21 every 28 days plus either high- (n = 38) or 
low-dose (n = 20) dexamethasone with the combination 
of lenalidomide 15 mg/day on days 1–14 every 21 days 
plus bortezomib 1.0 mg/m2 on days 1, 4, 8, and 11, and 
low-dose dexamethasone (n = 13).120 Currently, 50 patients 
have completed three cycles of therapy, including 38 of 
58 patients assigned to lenalidomide plus either high- or 
low-dose dexamethasone and 12 of 13 patients assigned to 
RVd. A total of 26 patients have received six cycles of therapy, 
including 19 of 58 patients assigned to lenalidomide and 
dexamethasone and seven of 13 patients assigned to RVd. 
The ORR was 58% in patients treated with lenalidomide 
and dexamethasone compared with 53% in patients treated 
with RVd.
Bevacizumab/lenalidomide/dexamethasone (Bev/Rev/Dex)
In a phase II study, 17 patients received four-weekly cycles 
of lenalidomide 25 mg/day on days 1–21, bevacizumab 
10 mg/kg as a two-hour infusion every two weeks, and 
dexamethasone 40 mg once a week.121 Among 10 evaluable 
patients who have completed at least four cycles of therapy, 
seven patients (70%) achieved a PR after a median of two 
cycles and have maintained their response.
Lenalidomide/melphalan/prednisone/thalidomide (RMPT)
In a phase II study, 43 patients (median age 69 years) were 
administered six cycles of lenalidomide 10 mg/day on days 
1–21 every 28 days, melphalan 0.18 mg/kg on days 1–4, 
prednisone 2 mg/kg on days 1–4, and thalidomide 50–100 
mg/day on days 1–28 followed by maintenance therapy of 
lenalidomide 10 mg/day.122 Therapy was administered as 
second-line in 61% of patients and third-line in 39%. After 
two cycles, 52% of patients achieved at least PR and after a 




In the MM-009 and MM-010 studies, TTP was the primary 
end point. The median TTP was significantly longer in patients 
assigned to lenalidomide plus dexamethasone compared with 
dexamethasone alone (MM-009: 11.1 months vs 4.7 months, 
respectively; P  0.001; MM-010: 11.3 months vs 4.7 months; 
P  0.001).2,97 TTP was also significantly longer in the 
lenalidomide plus dexamethasone group compared with 
dexamethasone alone in patients who had received prior 
thalidomide or bortezomib therapy, and in patients with 1 or 2 
prior therapies (Table 4). In a pooled analysis of all 704 patients 
in both studies, the median TTP in patients treated with 
lenalidomide plus dexamethasone versus dexamethasone 
alone was 11.2 months versus 4.7 months (P  0.001).97 
Response was related to TTP as among the patients treated 
with lenalidomide plus dexamethasone who achieved a 
CR or nCR, median TTP was significantly longer than 
those who achieved a PR (15.1 months vs 10.7 months; 
P  0.001).98
Among the 154 patients with IgA disease at baseline, 
median TTP was significantly longer in the lenalidomide 
plus dexamethasone group than in the dexamethasone-only 
group (10.3 months vs 3.8 months, respectively; P  0.001).101 
In patients without IgA disease, median TTP was again 
significantly longer in the lenalidomide plus dexamethasone 
group compared with dexamethasone alone (12.0 months vs 
4.7 months, respectively; P  0.001). Patients with a baseline 
ECOG score of 0 or 1 also had a significantly longer median 
TTP on lenalidomide plus dexamethasone (10.3 months 
and 13.3 months, respectively) than dexamethasone alone 
(4.7 months and 4.7 months, respectively; P  0.001 for 
both comparisons).102 Dexamethasone dose reduction was 
similarly associated with a longer TTP. In the pooled subgroup 
analysis of patients with renal impairment, median TTP was 
significantly longer for lenalidomide plus dexamethasone Core Evidence 2009:4 234
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compared with dexamethasone alone in patients with normal 
renal function (11.3 months vs 4.7 months, respectively; 
P  0.001), and mild (12.1 months vs 4.7 months; 
P  0.001), moderate (11.4 months vs 2.8 months; P  0.001), 
and severe (7.9 months vs 4.7 months; P = 0.031) renal impair-
ment104 (Table 5). In another subgroup analysis of patients who 
received lenalidomide plus dexamethasone, dose reduction of 
dexamethasone was associated with significantly longer TTP 
than continuing dexamethasone according to the planned 
dosing schedule (13.9 months vs 5.6 months, respectively; 
P = 0.002).105
Single-agent lenalidomide
Among 222 patients enrolled in the multicenter, open-label 
phase II MM-014 study, 69% of patients had disease pro-
gression by the end of the study with a median TTP of 
5.4 months.112
RAD
In a phase I/II study of 41 patients treated for six 28-day cycles 
with lenalidomide 25 mg/day on days 1–21, doxorubicin 
9 mg/m2 on days 1–4, dexamethasone 40 mg/day on days 1–4 
and 17–20, and G-CSF 6 mg on day 6, median TTP after a 
median follow-up of five months was 9.3 weeks.117
Overall survival
Lenalidomide plus dexamethasone
Relative to dexamethasone alone, median OS was signifi-
cantly prolonged in patients assigned to lenalidomide plus 
dexamethasone in both the MM-009 and MM-010 studies.2,3 
At a median follow-up post-randomization of 17.1 months 
in the MM-009 study, the median OS in patients assigned to 
lenalidomide plus dexamethasone was 29.6 months versus 
20.2 months for dexamethasone alone (P  0.001).3 Simi-
larly, at a median follow-up of 16.5 months in the MM-010 
study, the median OS in patients assigned to lenalidomide 
plus dexamethasone had not been reached, whereas in 
patients assigned to dexamethasone-only median OS was 
estimated at 20.6 months (P = 0.03).2 With an extended 
follow-up of 31.3 months, the median OS for all 704 patients 
pooled from both studies was 35.0 months for those receiving 
lenalidomide plus dexamethasone and 31.0 months for those 
on dexamethasone alone (P  0.05).97 It should be noted 
that this significant difference in OS was maintained despite 
47% of patients receiving dexamethasone alone crossing over 
to lenalidomide plus dexamethasone therapy.97 Response 
was correlated with survival because among patients 
assigned to lenalidomide plus dexamethasone the median 
OS was significantly higher for those who achieved CR or 
nCR, than for patients who achieved a PR (30.9 months 
vs 27.5 months, respectively; P  0.01).98
In both MM-009 and MM-010, OS was significantly 
improved in the lenalidomide plus dexamethasone group 
compared with the dexamethasone-only group, among 
patients who had previously been treated with thalidomide.2,3 
In addition, lenalidomide plus dexamethasone was associated 
with significantly longer OS compared with dexamethasone 
alone, irrespective of the number of prior therapies.97,123 
In a pooled analysis of all 704 patients, the median OS was 
not yet reached in patients assigned to the lenalidomide 
plus dexamethasone group who had received one prior 
therapy compared with 35.3 months in patients assigned 
to dexamethasone alone (P = 0.24).97 In patients who had 
received 1 prior therapy, median OS was 32.4 months in 
those assigned to lenalidomide plus dexamethasone compared 
with 27.3 months in those assigned to dexamethasone alone 
(P  0.05).
In patients with IgA disease at baseline, there was 
a trend towards improved OS with lenalidomide plus 
dexamethasone treatment compared with dexamethasone 
alone (30.3 months vs 23.8 months, respectively; P = not 
significant).101 In patients without IgA disease at baseline, there 
was a significant benefit in terms of OS for lenalidomide plus 
dexamethasone versus dexamethasone alone (36.3 months vs 
31.7 months, respectively; P  0.05). Similarly, patients with 
an ECOG performance status of 0 at baseline had a similar 
median OS with lenalidomide plus dexamethasone relative 
to dexamethasone alone (36.3 months vs 37.0 months, 
respectively; P = not significant).102 However, among patients 
with an ECOG score 1, median OS was significantly higher 
in patients assigned to lenalidomide plus dexamethasone 
versus dexamethasone alone (32.9 months vs 24.1 months, 
respectively; P  0.01). When patients were stratified accord-
ing to renal function, there was a trend towards improved 
OS with lenalidomide plus dexamethasone compared with 
dexamethasone alone in patients with moderate renal impair-
ment (30.4 months vs 12.5 months, respectively; P = 0.068)104 
(Table 5). However, OS was not significantly different for those 
with normal renal function (not reached vs 101.2 months, 
respectively; P = 0.142), mild renal impairment (34.7 months 
vs 27.2 months; P = 0.131) or severe renal impairment 
(18.6 months vs 16.9 months; P = 0.849). Among patients 
who were assigned to lenalidomide plus dexamethasone, 
dose reduction of dexamethasone was associated with a trend 
towards improved OS compared with patients who were 
maintained on the planned dexamethasone dose regimen 
(28.3 months vs 25.5 months, respectively; P = 0.19).105Core Evidence 2009:4 235
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In the MM-009/ and MM-010 studies, 47% of patients 
randomized to dexamethasone alone later switched to 
lenalidomide plus dexamethasone at disease progression or 
following ethical study unblinding.124 In a survival analysis 
that adjusted for the overestimation of survival in the group 
treated with dexamethasone alone, Morgan and colleagues 
reported that treatment of patients who had one prior therapy 
with single-agent dexamethasone yielded a median survival of 
16.2 months compared with 33.6 months following crossover 
to lenalidomide plus dexamethasone.124 The median survival 
for patients with multiple prior therapies was 12.6 months 
compared with 27.3 months with crossover to lenalidomide 
plus dexamethasone. Using a lifetime simulation model, 
Morgan and colleagues estimated a mean survival of 2.2 
life-years with dexamethasone alone compared with 5.6 life-
years with lenalidomide plus dexamethasone for patients with 
one prior therapy. For patients with multiple prior therapies, 
lifetime simulation yielded an estimated mean survival of 
1.5 life-years for dexamethasone alone compared with 4.2 
life-years for lenalidomide plus dexamethasone.
The MM-016 study was a multicenter, single-arm, 
open-label expanded access program for lenalidomide in 
relapsed and refractory MM that reported on the efficacy of 
lenalidomide plus dexamethasone in patients according to 
their del13q, t(4; 14), and del17p13 status. Patients received 
lenalidomide 25 mg/day on days 1–21 of a 28-day cycle, plus 
dexamethasone 40 mg/day on days 1–4, 9–12 and 17–20 for 
four cycles, then days 1–4 only beginning with cycle 5.125 
In the entire group, progression-free survival (PFS) was 
10.6 months and the median OS was not reached at a median 
follow-up of 16 months. Compared with the overall cohort, 
treatment with lenalidomide plus dexamethasone overcame 
poor prognosis conferred by del13q and t(4; 14) cytogenetic 
abnormalities, with no increased risk of a reduction in OS 
(del13q: hazard ratio [HR], 0.56, 95% confidence interval 
[CI] 0.25–1.29; P = 0.179; and t(4; 14): HR, 1.26, 95% CI 
0.46–3.42; P = 0.641). However, patients with del17p13 had 
a reduced OS despite a rapid initial response to therapy (HR, 
3.83; 95% CI 1.34–10.93; P = 0.012).
In a preliminary analysis of 42 patients with relapsed or 
refractory MM treated with lenalidomide and dexametha-
sone in an ongoing Dutch compassionate need program, the 
median OS has not been reached (median PFS 10 months).106
Single-agent lenalidomide
In an open-label, phase II study of 102 patients, at a median 
follow-up of 31 months, lenalidomide 30 mg/day was associated 
with a median OS of 27 months. There was no significant 
survival advantage reported for patients who received 30 mg 
once-daily dosing versus 15 mg twice daily.107 In the multi-
center, open-label, phase II MM-014 study of 222 patients, 
in which concomitant dexamethasone was not permitted, 
three-year OS was 41%, with a median OS of 1.9 years.112
Lenalidomide and bortezomib
Overall survival in the lenalidomide plus bortezomib is 
emerging at 37 months.
Lenalidomide plus prednisone
Among 69 patients who received lenalidomide plus 
corticosteroids (pulsed dexamethasone or prednisone) as 
part of an Expanded Access Program in Canada, OS was 
74% in patients aged 65 years compared with 76% in 
patients 65 years.118
RAD
In a phase I/II study of 41 patients treated for six 28-day 
cycles with lenalidomide 25 mg/day on days 1–21, doxorubi-
cin 9 mg/m2 on days 1–4, dexamethasone 40 mg/day on days 
1–4 and 17–20, and G-CSF 6 mg on day 6, after a median 
follow-up of five months OS was 79%.117
Safety and tolerability
In the two pivotal phase III studies of relapsed or refractory 
MM, grade 3 or 4 adverse events were reported more frequently 
in patients assigned to lenalidomide plus dexamethasone 
compared with dexamethasone alone.2,3 In the MM-009 study, 
grade 3 or 4 hematologic adverse events in the lenalidomide 
plus dexamethasone versus dexamethasone-only groups were 
neutropenia (41.2% vs 4.5%, respectively), anemia (13.0% 
vs 5.1%), thrombocytopenia (14.7% vs 6.9%), and febrile 
neutropenia (3.4% vs 0%). Other commonly occurring grade 
3 or 4 adverse events were any infection (21.4% vs 12.0%, 
respectively), pneumonia (12.4% vs 7.4%), hyperglycemia 
(10.8% vs 8.6%), hypokalemia (6.2% vs 1.1%), and fatigue 
(6.2% vs 6.3%). VTE events occurred in 14.7% of patients 
in the lenalidomide plus dexamethasone group compared 
with 3.4% of patients in the dexamethasone-only group 
(P  0.001).3 In the MM-010 study, grade 3 or 4 hemato-
logic adverse events in the lenalidomide plus dexamethasone 
versus dexamethasone-only groups were neutropenia (29.5% 
vs 2.3%, respectively), anemia (8.6% vs 6.9%), thrombocy-
topenia (11.4% vs 5.7%), and febrile neutropenia (3.4% vs 
0%). Other commonly occurring grade 3 or 4 adverse events 
were any infection (11.3% vs 6.2%, respectively), muscle 
weakness (7.4% vs 4.6%), asthenia (6.2% vs 5.7%), and 
fatigue (6.8% vs 3.4%). Grade 3 or 4 VTE events occurred Core Evidence 2009:4 236
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in 11.4% of patients in the lenalidomide plus dexamethasone 
group compared with 4.6% of patients in the dexamethasone-
only group.2
The increased incidence of VTE in patients receiving 
lenalidomide plus dexamethasone compared with dexametha-
sone alone does not appear to affect survival. In an analysis of 
177 patients assigned to receive lenalidomide plus dexametha-
sone in the MM-009 study, OS (P = 0.4) and TTP (P = 0.7) were 
not significantly different for the 31 patients who experienced 
DVT compared with patients who did not experience DVT.126 
In the MM-009 and MM-010 studies, multivariate analysis 
indicated that lenalidomide plus dexamethasone treatment 
with adjunctive erythropoietin was independently correlated 
with thrombosis; older age, lower plasma cell involvement 
in the bone marrow, and better ECOG performance status 
had a weaker association with thrombosis.127 None of the 
23 patients who used aspirin during the first month of treat-
ment developed thromboses; all events occurred in patients 
with rising M-protein levels at baseline.
In the MM-009 and MM-010 studies, the predominant 
reason for adjusting dexamethasone dose among patients 
assigned to lenalidomide plus dexamethasone was for an 
adverse event (41 of 46 patients).105 In this group of patients, 
reducing dexamethasone dose yielded a similar safety profile 
to those who did not require dose reductions. Grade 3 or 4 
hematological events in patients who received dexametha-
sone dose reductions relative to those who maintained the 
planned dexamethasone dose were: neutropenia (23.7% vs 
32.6%, respectively), thrombocytopenia (8.5% vs 6.8%), and 
anemia (6.8% vs 6.2%).
Among 1,400 patients with relapsed or refractory MM 
who were administered lenalidomide 25 mg plus high-dose 
dexamethasone in 28-day cycles as part of an expanded 
access program in North America, the most commonly 
reported grade 3 or 4 adverse events were: neutropenia 
(7.9%), thrombocytopenia (6.0%), fatigue (3.6%), anemia 
(3.5%), pneumonia (3.1%), and hyperglycemia (2.0%).128 
Although the grade 3 or 4 adverse events were the same as 
those reported in the two phase III studies, their frequencies 
were lower. Likewise, the most commonly reported adverse 
events of all grades were the same as those reported in the 
two pivotal studies.
The findings of a recent analysis of 72 patients receiving 
lenalidomide plus dexamethasone as first-line therapy 
indicate that myelosuppression is associated with renal 
dysfunction.129 In this analysis, eight of 14 patients with grade 
3 or 4 myelosuppression had a baseline CrCl of 40 mL/min, 
with Kaplan–Meier analysis showing a significant association 
between renal insufficiency and time to myelosuppression. 
In the subgroup analysis of patients in the MM-009 and 
MM-010 studies, patients with renal impairment at baseline 
tended to have an increased incidence of thrombocytopenia 
compared with those with normal renal function.104 In patients 
treated with lenalidomide plus dexamethasone, the incidences 
of neutropenia and thrombocytopenia increased among 
those with normal renal function from 31.0% and 7.0%, 
respectively, to 39.2% and 16.0% for mild renal impairment, 
and to 42.9% and 19.0% for moderate renal impairment, 
respectively. The incidences of neutropenia and thrombocy-
topenia among the 16 patients with severe renal impairment 
were 37.5% and 37.5%, respectively. In the dexamethasone-
only arm, the incidences of neutropenia and thrombocytopenia 
among those with normal renal function were 4.3% and 
5.5%, respectively (P  0.001 and P = 0.649 relative to 
the lenalidomide plus dexamethasone arm), compared with 
1.5% and 5.3% in patients with mild renal impairment 
(P  0.001 and P = 0.007), 5.9% and 17.6% for moderate renal 
impairment (P  0.001 and P = 1.00), and 8.3% and 0% in 
the 12 patients with severe renal impairment (P = 0.184 and 
P = 0.024), respectively. There were no significant differences 
in the incidences of thrombotic episodes in lenalidomide plus 
dexamethasone versus dexamethasone-only patients with 
mild (12.0% vs 6.1%, respectively; P = 0.126), moderate 
(14.3% vs 2.9%; P = 0.122), or severe (6.3% vs 8.3%; 
P = 1.00) renal impairment.
In a pooled analysis of the MM-009 and MM-010 studies, 
the incidence of diarrhea was 39% in the lenalidomide plus 
dexamethasone arm compared with 28% in the dexamethasone-
only arm.130 Multivariate analysis found that therapy duration 
but not treatment assignment predicted diarrhea. Among a 
cohort of patients who received 9–15 months of therapy, the 
incidence of diarrhea after adjustment for treatment duration 
was similar for lenalidomide plus dexamethasone versus 
dexamethasone alone (42.3% vs 42.5%, respectively), sug-
gesting that the risk of unexpected diarrhea with long-term 
therapy may be partly attributable to dexamethasone, but it 
is important to note that mild-to-moderate diarrhea is a well 
recognized effect of lenalidomide monotherapy, particularly 
with prolonged use.
As a single-agent therapy in the relapsed or refractory 
MM setting, lenalidomide is again associated with 
myelosuppression. In a phase I dose-escalation study of 
lenalidomide 5–50 mg/day, neutropenia was the most 
common adverse event, with grade 3 neutropenia occurring 
in 15 of 25 (60%) patients and grade 4 neutropenia in four 
of 25 (16%) patients.113 Grade 3 thrombocytopenia occurred Core Evidence 2009:4 237
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in five of 25 (20%) patients. In a phase II study evaluating 
lenalidomide 30 mg once-daily versus 15 mg twice-daily, an 
increased incidence of cytopenia was noted in the twice-daily 
group, prompting a once-daily schedule moving forward.107 
In a long-term follow-up of 15 patients treated initially with 
either 30 mg once daily (n = 11) or 15 mg twice daily (n = 4), 
with or without the addition of dexamethasone, the most com-
mon grade 3 or 4 toxicity was neutropenia, which occurred 
in 10 patients.108 No grade 3 or 4 thrombocytopenia, anemia, 
peripheral neuropathy, or DVT was reported. In a subsequent 
phase II study of 222 patients with relapsed or refractory MM, 
the most frequent grade 3 or 4 toxicities with single-agent 
lenalidomide 30 mg once daily given on days 1–21 of every 
28-day cycle were neutropenia (60%), thrombocytopenia 
(39%), and anemia (20%).112 However, the incidence of DVT 
and febrile neutropenia was low (both 4%).
Prior to receiving regulatory approval, both thalidomide 
and lenalidomide were associated with VTE incidences 20% 
when combined with dexamethasone for use as an off-label 
treatment for MM.131 In a systematic review of VTE rates, 
a search of the US FDA’s MedWatch program found reports 
of VTE among eight lenalidomide-treated cancer patients, 
including three receiving aspirin prophylaxis, two on warfarin, 
and one on low-molecular-weight heparins.131 Clinical trials 
identified VTE in 38 of 278 (13.7%) previously untreated 
patients and 48 of 346 (13.9%) relapsed or refractory MM 
patients receiving lenalidomide plus dexamethasone. None of 
these patients received routine thromboprophylaxis. In another 
systematic review, VTE rates ranged from 8.5%–75% in 
MM patients treated with lenalidomide and dexamethasone 
or erythropoietin. However, with the addition of aspirin this 
rate was 3.4%.132 NCCN guidelines currently recommend 
anticoagulation therapy in patients treated with lenalido-
mide plus dexamethasone.27 However, controlled studies 
may be needed to identify optimal thromboprophylaxis for 
patients treated with lenalidomide and dexamethasone.
In combination with bortezomib 1.0 mg/m2 and dexa-
methasone 20 mg/10 mg, lenalidomide 15 mg administered 
for up to eight cycles is associated with manageable toxici-
ties consisting mainly of grade 1 or 2 myelosuppression.119 
Attributable nonhematologic toxicities were DVT in two of 
41 patients, grade 3 atrial fibrillation in two patients, and grade 
3 peripheral neuropathy in one patient. Dose reductions were 
required for lenalidomide in nine patients, bortezomib in five 
patients, and dexamethasone in 14 patients.
The combination of lenalidomide 10 mg/day with 
melphalan 0.18 mg/kg, prednisone 2 mg/kg and thalidomide 
50–100 mg was generally well tolerated in patients 
who received up to six cycles of therapy as second- or 
third-line treatment.122 The most frequent adverse events 
were hematologic, with 48% of patients experiencing grade 
3 neutropenia and 16% experiencing grade 4 neutropenia. 
Grade 3 and 4 thrombocytopenia were reported in 26% and 
10% of patients, respectively. Growth factor support was 
required in 39% of patients and one1 patient required platelet 
transfusion. The most frequent nonhematologic toxicity was 
infection in 19% of patients. No VTE events were detected.
In 41 patients treated with lenalidomide 25 mg (days 
1–21) in combination with doxorubicin 9 mg/m2 (days 1–4), 
dexamethasone 40 mg (days 1–4 and 17–20), and G-CSF 
6 mg, grade 3 or 4 infection occurred in 10% of patients 
and VTE occurred in 5%.117 Eight patients prematurely 
discontinued due to catheter-related septicemia (n = 2), 
thrombosis of basal artery (n = 1), prolonged pneumonia 
(n = 1), or withdrawal of consent (n = 4). Adverse events 
were generally of moderate severity and manageable.
Ongoing clinical development
The encouraging results of the two pivotal phase III studies 
demonstrating that lenalidomide in combination with 
dexamethasone significantly prolongs survival compared 
with dexamethasone alone, has led to further studies in previ-
ously treated MM patients. Among the phase III or IV studies 
currently being conducted in this setting, lenalidomide 
is being evaluated in combination with: dexamethasone; 
bortezomib and dexamethasone; and dexamethasone with 
or without thalidomide. Lenalidomide is additionally being 
evaluated as maintenance therapy following ASCT. Other 
investigational combinations currently being investigated in 
phase I and II trials include lenalidomide plus dexamethasone 
in combination with each of the following: panobinostat, 
bevacizumab, SGN-40, perifosine, vorinostat, dasatinib, 
NPI-0002, and carfilzomib. Lenalidomide is also being 
studied in combination with everolimus, and as monotherapy 
in patients who have relapsed on prior SCT.
The finding that lenalidomide in combination with 
dexamethasone yields high objective response and survival 
rates at one-, two-, and three-year follow-up has also 
encouraged further research in newly diagnosed MM. In this 
setting, lenalidomide is being evaluated in phase III studies 
as single-agent therapy (melphalan/prednisone/thalidomide 
and single-agent dexamethasone as comparators), and for 
use in combination with dexamethasone, and melphalan and 
prednisone in patients aged 65 years. There is now evidence 
that initial induction therapy with a lenalidomide-based 
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CD34+ positive stem cells for autologous SCT, but appears 
to be dependent on mobilization using a combination of 
G-CSF and cyclophosphamide, or similar.94–96 Numerous 
phase I and II studies are currently investigating lenalidomide 
combination regimens in previously untreated patients 
including lenalidomide and bortezomib plus dexamethasone, 
with or without cyclophosphamide, and lenalidomide and 
bortezomib plus dexamethasone and doxorubicin. Lenalido-
mide is additionally being evaluated as maintenance therapy 
following autologous SCT.
Economic evidence and resource 
utilization
Limited information on the health economics of lenalidomide 
in MM comes from a budget impact model comparing 
resource utilization of four approved therapies in the 
US.133 This study used a managed-care payer perspective 
to assess resource utilization in MM associated with each 
of single-agent bortezomib, bortezomib plus pegylated 
liposomal doxorubicin, thalidomide plus dexamethasone, 
and lenalidomide plus dexamethasone. Drug costs were 
calculated based on average wholesale price less 15%, with 
a 10% patient coinsurance contribution for thalidomide plus 
dexamethasone and lenalidomide plus dexamethasone, and 
a 20% patient contribution for single-agent bortezomib and 
bortezomib plus doxorubicin. Costs of therapy and costs of 
treating adverse events were based on standard sources or 
from peer-reviewed publications and/or meeting presenta-
tions. Incidences of adverse events, and assumptions for 
supportive care and prophylaxis were obtained from the 
prescribing information for each of the approved therapies 
and from published reports of pivotal phase III trials. Dura-
tion of therapy was based on the published median duration 
of therapy.
In this model, total costs for each of the four regimens were 
primarily driven by direct drug costs, with an acquisition cost 
of US $64,806 for the combination of lenalidomide plus dexa-
methasone.133 This represented a 1.7-fold increase on drug 
costs for the thalidomide plus dexamethasone combination, 
and a 1.9-fold increase on drug costs for the bortezomib 
plus doxorubicin combination. However, associated medical 
costs of lenalidomide plus dexamethasone (US $1,623) were 
comparable to thalidomide plus dexamethasone, and less 
than a quarter of that of bortezomib plus doxorubicin. Costs 
attributable to adverse events were again favorable for the 
lenalidomide plus dexamethasone combination (US $5,243), 
representing a cost-saving of US $2,667 compared with 
thalidomide plus dexamethasone, and US $851 compared 
with bortezomib plus doxorubicin. The total cost of the 
lenalidomide plus dexamethasone regimen including cost 
of prophylaxis for DVT and pulmonary embolism was 
US $72,822, which represents a 1.5-fold higher total cost 
compared with either thalidomide plus dexamethasone, or 
bortezomib plus doxorubicin.
This study has several weaknesses of which the most 
important is that it does not account for differences in 
efficacy as a function of cost. No consideration was given 
to the patient populations, which in the pivotal phase III 
trials of lenalidomide involved a heavily pretreated popula-
tion with relapsed or refractory disease, with a consequent 
impact on duration of therapy and adverse events. As oral 
drugs, lenalidomide and thalidomide in combination with 
dexamethasone would be expected to offer an improvement 
in health-related quality of life compared with combination 
bortezomib plus doxorubicin, which are administered as 
intravenous infusions. However, this study offers a starting 
point for comparisons between MM therapies and is a valid 
approach to economic analysis from the viewpoint of the 
payer. Additional health economic studies of lenalidomide 
are required that include quality of life measures and data 
on the cost utility of treatment.
In a chart review conducted in five university hospitals in 
France during the period 2004–2007, the total direct costs of 
usual care of patients with relapsed or refractory MM were 
estimated at  73, 000 per patient from first relapse until death 
or last follow-up.134 The study included a total of 102 patients 
with a mean age at diagnosis of 59 years and a mean of 2.8 lines 
of therapy since first relapse. Novel agents were used in 205 
of 281 lines (73%) and consisted of thalidomide combination 
therapy (28%), bortezomib (22%), lenalidomide (13%), and 
bortezomib plus thalidomide (10%). The average cost per line 
was  26, 510 including  17,525 for drugs. With respect to 
the third-line of treatment, lenalidomide-based therapy was 
similar to bortezomib: mean duration and cost of treatment 
for lenalidomide was 7.4 months and  46,724 compared 
with 6.9 months and  46,321 for bortezomib.
Deniz and colleagues used a discrete event simula-
tion model to estimate the long-term health and cost 
consequences of lenalidomide plus dexamethasone versus 
dexamethasone-alone in MM patients who received 
either 1 or 2 prior therapies.135 The model used patient 
responses to treatment and time-to-event data based on 
Weibull functions derived from pooled data from the 
MM-009 and MM-010 clinical studies. Long-term results 
from UK Medical Research Council-sponsored trials and 
Mayo Clinic data were used to calculate dexamethasone Core Evidence 2009:4 239
Lenalidomide: place in therapy review Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
survival given that 47% of patients in the dexamethasone 
arm of the MM-009 and MM-010 trials crossed over to 
receive lenalidomide treatment following disease progres-
sion or ethical unblinding. Disease management costs were 
reflective of clinical practice in Wales, UK. Cost and health 
outcomes were discounted at 3.5% per annum to adjust 
to present values. Events and costs were considered over 
two years to reflect trial follow-up, whereas survival and 
quality-adjusted life years (QALYs) were modeled to end 
of life to avoid truncation bias. In patients with one prior 
therapy, lenalidomide plus dexamethasone was associated 
with improvements in both survival and QALYs (4.54 
projected mean life years and 3.20 QALYs) compared with 
dexamethasone alone (2.00 and 1.39, respectively). This 
equated to an incremental cost per life year gained of £20,617 
and per QALY gained of £28,943 in patients receiving 
lenalidomide. Similarly, in patients with at least two prior 
therapies, lenalidomide plus dexamethasone was associated 
with a projected mean survival of 3.61 life years and 2.50 
QALYs compared with 1.41 life years and 1.00 QALYs for 
dexamethasone alone. The incremental cost of lenalidomide 
per life year gained in this group of patients was £19,218 
and £28,184 per incremental QALY gained.
Patient group/population
The evidence to support lenalidomide in its licensed 
indication for use in combination with dexamethasone 
for the treatment of patients with relapsed or refractory 
MM who have undergone at least one prior therapy was 
predominantly derived from two pivotal phase III studies that 
compared lenalidomide plus high-dose dexamethasone with 
dexamethasone alone.2,3 MM-009 was conducted in 48 centers 
in the USA and Canada, and MM-010 was conducted in 
51 centers in Europe, Australia, and Israel. The median age 
of patients was 63 years, most were male, and most had an 
ECOG performance status of 0 or 1. Approximately 65% of 
patients had Durie–Salmon stage III disease at diagnosis, 
three-quarters of patients had lytic disease, and a third had 
bone marrow involvement. A total of 61% of patients enrolled 
in MM-009 and 55% of patients in MM-010 had previously 
received at least one prior SCT, and most had received 2 
previous lines of treatment. In MM-009, 10% of patients 
had previously received bortezomib, 44% had received 
thalidomide, and 60% had received dexamethasone. The 
respective data for patients enrolled in MM-010 were 4%, 
34%, and 67%.
The patients enrolled in these studies represented a 
heavily pretreated population with advanced disease. A high 
proportion of patients (40.5%) were aged 65 years.136 Of 
the elderly group, the median time to diagnosis was approxi-
mately 3.3 years, and three-quarters had received 2 prior 
therapies, including dexamethasone in 69% and thalidomide 
in 32% of patients. However, the clinical benefit of lenalido-
mide plus dexamethasone in terms of response, TTP, and OS 
was comparable with younger patients.
Of the 353 patients in MM-009 and MM-010 who were 
randomized to receive lenalidomide plus dexamethasone, 
210 (59.5%) had previously undergone autologous SCT.137 
In a subgroup analysis comparing outcomes in patients 
with prior autologous SCT and no prior autologous SCT, 
there were no significant differences in ORR (63% vs 55%, 
respectively) or CR rate (13% vs 16%; P = 0.12). There was 
a trend towards prolonged TTP in patients without prior 
autologous SCT (14.2 vs 10.2 months for previous autolo-
gous SCT; P = 0.13). An interesting observation was that the 
median time from first pathologic diagnosis was similar for 
the two groups (3.4 years in the prior autologous SCT group 
vs 2.9 years in the no prior autologous SCT group). Based on 
the TTP trend, this observation implies that patients who have 
not had a chance to benefit from autologous SCT may receive 
an advantage from lenalidomide plus dexamethasone therapy, 
and provides a rationale for commencing lenalidomide-based 
therapy early in the disease course.137 This is further supported 
by the findings of a subgroup analysis, which suggested there 
was an advantage for second-line compared with later salvage 
treatment in terms of response rate and TTP.100
Thus, in patients with relapsed or refractory disease, the 
data indicate that treatment with lenalidomide plus dexa-
methasone is suitable as early or later salvage therapy in 
a broad group of patients. In particular, lenalidomide plus 
dexamethasone is effective at prolonging TTP indepen-
dently of patient age, number or type of previous therapies 
including previous autologous SCT, and β2-microglobulin 
status.2,3 Moreover, the combination of lenalidomide plus 
dexamethasone is effective at prolonging OS irrespective of 
prior thalidomide use or the number of previous therapies; 
OS is also improved in patients with IgA disease at baseline 
and in patients with an ECOG performance status 0.2,3,101,102 
In the relapsed or refractory setting, lenalidomide is emerging 
as a suitable partner for bortezomib, with nonoverlapping 
toxicities and a high rate of response.62,119
There is now increasing evidence to support a role for 
lenalidomide-based regimens as a first-line option where 
ORR  90% have been reported, including CR rates of 
18%–25%.43,83,129 In newly diagnosed patients with ASIPs, 
the BiRD combination of lenalidomide, clarithromycin, Core Evidence 2009:4 240
Richardson et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and dexamethasone (BiRD) is associated with a CR rate of 
71% and a VGPR or better rate of 96%.88
Dosage, administration,  
and formulation
Lenalidomide (CC-5013, Revlimid®), an immunomodulatory 
drug with antitumor, antiangiogenesis, and apoptotic activi-
ties, is an analog of thalidomide with more potent activity 
and a different tolerability profile. It is available for oral 
administration in 5 mg, 10 mg, 15 mg, and 25 mg capsules. 
Lenalidomide is indicated in combination with dexametha-
sone for the treatment of patients with MM who have received 
at least one prior therapy. The recommended starting dose is 
25 mg/day with water, administered as a single 25 mg capsule 
on days 1–21 of a repeated 28-day cycle. The recommended 
dose of dexamethasone is 40 mg/day on days 1–4, 9–12, and 
17–20 of each 28-day cycle for the first four cycles of therapy, 
and then at a dose of 40 mg/day on days 1–4 every 28 days. 
Dose modifications and interruptions are recommended to 
manage grade 3 or 4 neutropenia or thrombocytopenia, or 
other grade 3 or 4 lenalidomide-associated toxicities.138 In 
thrombocytopenia, when platelets fall to 30,000 per µL, 
lenalidomide treatment should be interrupted and follow-up 
complete blood counts performed weekly until recovery is 
confirmed (30,000 per µL). Treatment should be restarted 
at 15 mg/day. For each subsequent platelet fall to 30,000 
per µL, treatment should again be interrupted and resumed 
at 5 mg less than the previous dose when platelet levels 
recover to 30,000 per µL. In neutropenia, when the absolute 
neutrophil count (ANC) falls to 1000 per µL, lenalidomide 
treatment should be interrupted and treatment with G-CSF 
initiated with weekly follow-up complete blood counts. 
When the ANC increases to 1000 per µL and neutrope-
nia is the only toxicity, lenalidomide should be resumed at 
25 mg/day or at 15 mg/day if there is another toxicity. For each 
subsequent fall to 1000 per µL, treatment should again be 
interrupted and resumed at 5 mg less than the previous dose 
when the ANC recovers to 1000 per µL. For other grade 3 
or 4 toxicities related to lenalidomide, treatment should be 
interrupted and restarted at the next lower dose level when 
the toxicity has resolved to grade 2 or lower. Lenalidomide 
should not be dosed below 5 mg/day.138
Place in therapy
In patients with relapsed or refractory MM who have received 
1–3 prior lines of therapy, lenalidomide in combination 
with high-dose dexamethasone produces significant 
prolongation of TTP and OS compared with high-dose 
dexamethasone alone.2,3 In patients with previously untreated 
MM, lenalidomide in combination with low-dose dexametha-
sone produces a significant survival advantage compared 
with lenalidomide plus high-dose dexamethasone.84,90 In 
both the newly diagnosed and relapsed or refractory settings, 
the addition of lenalidomide to high-dose dexamethasone is 
associated with a higher rate of grade 3 or 4 myelosuppres-
sion, and in the absence of appropriate thromboprophylaxis, 
a higher rate of VTE events compared with high-dose dexa-
methasone alone.2,3,43,139 However, there is level 2 evidence 
from the MM-009 study that survival is not affected by 
occurrence of DVT.126
The MM-009 and MM-010 pivotal phase III studies 
provided level 2 evidence in support of lenalidomide plus 
dexamethasone in the relapsed or refractory setting. After 
a median follow-up of 17.1 months post-randomization, 
median OS in the lenalidomide plus high-dose dexametha-
sone group was 29.6 months in MM-009 and not yet reached 
in MM-010.2,3 In comparison, median OS in the placebo 
plus high-dose dexamethasone group was 20.2 months in 
MM-009 and 20.6 months in MM-010. Thus, the addition 
of lenalidomide to high-dose dexamethasone in patients who 
have received 1–3 prior therapies is likely to prolong median 
survival by approximately nine months. After adjusting for 
crossover of patients initially assigned to dexamethasone 
alone into the lenalidomide arm, prolongation of survival is 
likely to be further enhanced.124 Level 2 evidence is available 
in support of this regimen in patients with one or more than 
one prior lines of therapy,100 in patients with or without previ-
ous thalidomide exposure,99 in patients with or without prior 
autologous SCT,137 and in patients with mild-to-moderate 
renal impairment.104 Furthermore, there is level 2 evidence 
in support of this regimen in patients aged 65 years and in 
those aged 65 years.136
There is level 2 evidence in support of lenalidomide plus 
dexamethasone in patients with newly diagnosed MM from 
two phase III studies.83,84,90,91 In one study, the investigators did 
not directly compare the lenalidomide-based regimen with 
a recognized therapy (ie, dexamethasone alone).84,90 Instead, 
patients in each arm received lenalidomide with either 
high-dose or low-dose dexamethasone. OS was significantly 
superior in the low-dose dexamethasone group (one-year OS 
96% vs 88% in the high-dose dexamethasone group; two-year 
OS 87% vs 75% in the high-dose group).84 These data com-
pare favorably with other regimens in this setting, including 
bortezomib monotherapy (one-year survival 80%).109 In the 
second study, which compared lenalidomide plus dexametha-
sone with dexamethasone alone, patient accrual was stopped Core Evidence 2009:4 241
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early due to external data affecting the acceptability of the 
control arm.83 The one-year survival data did not favor either 
treatment arm (93% for lenalidomide plus dexamethasone 
vs 91% for dexamethasone alone). A subgroup analysis 
suggested the presence of abnormal cytogenetics at baseline 
was associated with a reduced one-year OS rate compared 
with no abnormal karyotype (one-year OS 82% vs 97%, 
respectively). High-risk cytogenetic abnormalities (HRCA) 
did not appear to account for this difference (one-year OS 
in patients with HRCA 100% vs 92% without HRCA); how-
ever, sample size limited the statistical power of this study.91 
Significant differences between the two treatment arms were 
observed in terms of response rates with lenalidomide plus 
dexamethasone yielding an ORR of 85.3% and a CR rate 
of 22.1% compared with 51.3% and 3.8%, respectively, for 
dexamethasone alone (P = 0.001).83
During clinical development of lenalidomide, it became 
apparent that addition of the drug to dexamethasone resulted 
in a higher rate of VTE events than dexamethasone alone. 
Although early trial protocols did not include thrombo-
prophylaxis, anticoagulation therapy with aspirin or low-
molecular weight heparin is now recommended. Given that 
anticoagulation therapy has been inconsistently applied 
during the lenalidomide clinical development program, it is 
difficult to assess the impact of anticoagulation therapy on 
VTE. However, level 4 evidence is available from a system-
atic review of published literature, abstracts, and package 
inserts to support the hypothesis that aspirin therapy reduces 
the incidence of VTE events to 5% of patients.132 A similar 
review that captured data for thalidomide as well as lenalido-
mide suggested that lower rates of VTE may be obtained 
using low-molecular-weight heparins.131 The authors of this 
review concluded that randomized clinical trials of antico-
agulation therapies are needed in order to identify appropriate 
prophylaxis when MM patients receive either lenalidomide 
or thalidomide with dexamethasone.
Overall, the current evidence base presented herein 
suggests that lenalidomide has significantly impacted the 
treatment of MM, and delivered survival benefits to both 
patients with newly diagnosed, or relapsed or refractory 
disease. Although lenalidomide is associated with an 
increased risk of grade 3 or 4 myelosuppression when com-
bined with dexamethasone, these risks can be mitigated 
through routine monitoring, dose interruptions, and growth 
factor support where appropriate. Adequate anticoagulation 
therapy is needed to minimize the risk of VTE, and in this 
regard further investigation is necessary to determine optimal 
treatment. The ability to combine lenalidomide with other 
agents (eg, bortezomib) is an important feature, and as such 
lenalidomide, together with bortezomib, thalidomide, and 
glucocorticoids, can be considered “backbone” agents as part 
of combination therapy in the treatment of MM.140
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